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Asthma is a multi-faceted chronic inflammatory disease accompanied by loss of 
airway epithelial integrity leading to remodeling of the airways. Perturbations to the lung 
redox environment, including alterations in glutathione (GSH) content, have been 
reported in asthma. GSH can be conjugated to protein cysteines, controlling protein 
function in an oxidant-dependent process known as protein S-glutathionylation (PSSG). 
The thioltransferase, glutaredoxin-1 (Glrx1), deglutathionylates proteins under 
physiological conditions, restoring sulfhydryl groups of target proteins. Glrx1 is 
emerging as a critical player in settings of allergic airway disease, but its function in 
regulating epithelial cell responses to asthma-relevant cytokines has not been examined. 
Furthermore, the role of Glrx1 in controlling the extent of airway remodeling in response 
to house dust mite (HDM) in vivo is still not well understood.  
Interleukin-17A (IL-17A) is a potent cytokine that stimulates epithelial cells to 
produce pro-inflammatory mediators, in part by activating the nuclear factor kappaB 
(NF-κB) pathway, a key regulator of inflammation. We demonstrate that interleukin-17A 
(IL-17A) induces rapid activation of both classical and alternative NF-κB, while 
simultaneously resulting in protein oxidation and PSSG. In particular, we show 
IL-17A-induces S-glutathionylation of RelA (RelA-SSG) and IKKα (IKKα-SSG), which 
is enhanced following siRNA-mediated knockdown of Glrx1. We also demonstrate that 
absence of Glrx1 leads to increased nuclear content of RelA and RelB and enhanced 
production of NF-κB-driven pro-inflammatory genes, KC and CCL20 while decreasing 
IL-6 expression. Finally, we show that siRNA-mediated knockdown of IKKα attenuates 
nuclear RelA and RelB and dampens pro-inflammatory gene production. Together, these 
data indicate a crucial role for the Glrx1/PSSG axis in controlling RelA-SSG, IKKα-SSG 
and epithelial cell responsiveness to IL-17A. 
Mice lacking Glrx1 were previously shown to display enhanced resolution of 
allergic airway disease induced by ovalbumin (Ova) challenge. In this study, we 
determined the role of Glrx1 in a HDM model of allergic airway disease. Wild type (WT) 
mice and Glrx1 deficient (Glrx1
-/-
) mice demonstrated similar total lung cell counts, but 
Glrx1
-/-
 mice displayed fewer neutrophils than WT mice. Conversely, mice 
overexpressing Glrx1 specifically in CCSP positive cells in the lung (Epi-Glrx1) showed 
attenuated total lung cell counts and lung eosinophils compared to control mice. 
Immunohistological analysis of remodeling markers revealed that Glrx1
-/- 
mice displayed 
increased HDM-induced mucus metaplasia, α-smooth muscle actin (αSMA) positivity 
and collagen staining compared to WT mice. Evaluation of total lung collagen showed 
that Glrx1
-/-
 mice had significantly higher collagen content compared to WT mice. In 
Epi-Glrx1 mice, attenuation of mucus metaplasia, αSMA content and collagen staining 
was observed compared to control mice. Furthermore, Epi-Glrx1 mice also demonstrated 
significantly impaired collagen production compared to control mice. We also 
demonstrate that Glrx1 absence results in decreased expression of the epithelial cell 
marker, E-cadherin, and increased expression of αSMA, a mesenchymal marker. 
Together, these studies demonstrate a critical role for Glrx1 in controlling epithelial cell 
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COMPREHENSIVE LITERATURE REVIEW 
Asthma 
Overview 
 Asthma is a chronic disease of the airways that affects approximately 25 million 
people in the U.S. and 300 million people worldwide. Typical characteristics of asthma 
include reversible airflow obstruction, chronic inflammation of the airways and airway 
hyperresponsiveness and are sometimes accompanied by development of irreversible 
airway remodeling. These features give rise to the clinical manifestations of asthma, 
consisting of tightening of the chest, wheezing and difficulty breathing, which can range 
from mild to severe.  Adding to the complexity of the disease, several different subtypes 
of asthma, recently termed ‘endotypes’, exist and include such classifications as exercise- 
or cold air-induced asthma, fixed airflow limitation (associated with neutrophilic influx) 
and allergic asthma [1]. For the purposes of this review, the focus will be on allergic 




Exposure to many allergens occurs on a daily basis (e.g. house dust mite), yet the 
exact mechanisms that lead to the development of allergic asthma remain largely 
unknown. This is due in large part to the heterogeneous nature of the disease. There is a 
general consensus that a genetic component exists, though validation of specific genetic 
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risk factors has proven difficult. One genome-wide association study (GWAS) concluded 
that risk of asthma development cannot be readily determined by genetic analysis, owing 
in part to differences observed in genes involved in development of childhood asthma 
versus late-onset asthma [2]. The same study, the largest GWAS done on asthma-related 
genes to date, also concluded that many genes implicated in disease pathogenesis appear 
to be involved in the communication of damaged epithelium with cells of the immune 
system, not necessarily polymorphisms associated with predisposition to the disease [2].  
The airway epithelium, discussed in greater detail in the next section, acts as a 
protective barrier between the external environment and the submucosa and can aid in 
coordinating immune responses via production of mediators that attract and activate 
immune cells. It is generally thought that events in the airway epithelium, including 
production of immune regulators IL-25, IL-33 and thymic stromal lymphopoeitin 
(TSLP), are the first step leading to downstream signaling events that drive a type 2 
immune response, characteristic of asthma. The type 2 response is distinguished by 
production of IL-4, IL-5 and IL-13, which correspond with high levels of airway 
eosinophils and production of IgE [3]. Although CD4+ T-helper 2 (Th2) cells were 
originally thought to be the major contributor of type 2 cytokines, there is strong 
evidence that the recently described type 2 innate lymphoid cells (ILC2s) may also be 
important in regulating asthma development [4]. ILC2s produce a cytokine profile similar 
to Th2 cells, but are unique in the cell surface receptors they express. For instance, ILCs 
do not express any T or B cell lineage markers; additionally, ILCs do not appear to be 
myeloid or erythroid in origin and are instead considered non-B non-T cell source of 
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Th2-associated cytokines [5, 6]. The presence of IL-25, IL-33 and TSLP in the lung can 
lead directly to activation of ILC2s, whereas the Th2 population requires communication 
with antigen presenting cells and a substantial lag period during expansion. Therefore, 
innate cells such as ILC2s may allow for more acute responses to allergens while the Th2 
population is undergoing clonal expansion.  
  More recently, there has been mounting evidence that Th2-associated asthma is 
just one aspect of a much more complex set of diverse phenotypes. This in part resulted 
from the discovery of the recently described CD4+ Th17 cell, characterized by the 
production of a unique panel of cytokines, including IL-17A and IL-22. In contrast to 
Th2 cytokines which are more involved in eosinophil recruitment and IgE production, 
IL-17A signaling in epithelial cells stimulates production of cytokines, such as KC 
(CXCL1; IL-8 in humans ), G-CSF and others, involved in the recruitment of neutrophils 
[7]. The resulting phenotype is dominated by a more destructive neutrophilic influx, and 
the presence of Th1 cells are often observed in abundance along with Th17 cells [8]. 
Asthmatics presenting with excessive IL-17A levels, both protein and mRNA, are often 
classified as having severe asthma, and IL-17A content in the sputum and serum is often 
used as a potential marker for severe asthma [9, 10], although the characteristics are often 
much more diverse. Th17 cells are thought to be the primary source of IL-17A [11, 12], 
but since their initial description, several other cell types have been shown to contribute 
to the IL-17A pool. Among these cells are γδ T cells [13], cytotoxic CD8+ (Tc17) T cells 
[14], invariant natural killer (iNKT) T cells [15] and ILC3s [16], many of which are 
involved in IL-17A production in the lung. There is evidence to suggest that neutrophils 
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and mast cells may also contribute to IL-17A production in synovial inflammation [17], 
although this has not been demonstrated in the setting of inflammatory lung diseases. 
A prominent role for various IL-17A-producing cells has been shown in lung 
disease, expanding beyond the Th17 paradigm [18]. ILC3s are similar to Th17 cells in 
that both rely on the transcription factor RORγt for proper functioning and both can 
express IL-17A, but like the aforementioned ILC2s, ILC3s lack any lineage markers [19, 
20]. Interestingly, ILC3-derived IL-17A can directly mediate AHR in a mouse model of 
obesity-induced asthma, independent of adaptive immunity [16]. ILC3s have also been 
observed in the BAL fluid of individuals suffering from asthma, further indicating the 
clinical importance of innate immune cells residing in the lung and participating in 
disease pathogenesis [16]. Specifics involved in IL-17 signaling and its involvement in 
inflammation will be discussed further in the next section. 
 
The Airway Epithelium 
Epithelial cells line the airways spanning the nasal cavities, trachea, bronchi and 
terminal bronchioles and are crucial in maintaining proper lung homeostasis. Previously, 
the epithelium was thought to act primarily as a physical barrier to pathogens and toxins 
and only after the epithelial layer was compromised and subsequently breached would an 
immune response be elicited. Recently, however, it has become apparent that the airway 
epithelium is not an innocent bystander in this process, but rather plays an active role in 
initiating and propagating immune responses [21]. Proper barrier function is exceedingly 
important and is a complex network of highly organized epithelial cell subtypes in the 
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conducting airways and in submucosal glands that produce mucus, surfactant proteins 
and several other components that aid in protection, killing and clearance of bacteria and 
viruses. Once trapped in the mucus layer, foreign material can stimulate the release of 
many of these factors, including β-defensins, amplifying the antimicrobial action of the 
epithelium [22]. Any offending material is then swept up the lung lining via mucociliary 
action where it is finally expelled from the airways. 
The conducting airways, including the trachea, bronchi and bronchioles, are 
largely pseudostratified and consist of three primary types of epithelial cells: ciliated, 
non-ciliated and basal cells. Of these subtypes, ciliated cells are the most abundant found 
in primates, making up over 50% of the epithelial cell population, compared to rodents in 
which secretory cells are the dominant epithelial cell type. Despite this inherent 
difference, both rodent and primate lungs contain basal cells that lie at the basement 
membrane and act as a foundation for other epithelial cell types. Basal cells are also 
important in that they can function as progenitor cells, aiding in repair and regeneration 
of damaged epithelium [23, 24]. Other prominent epithelial subtypes found on the airway 
surface include goblet cells, which are principally responsible for producing the large 
mucin glycoproteins that make up the complex mucus meshwork; serous cells, important 
in maintaining the proper hydration of mucus secreted by goblet cells; and club cells 
(formerly known as Clara cells), which secrete surfactant proteins [25], anti-proteases 
and CCSP (or CC10), which exhibits some immunosuppressive functions and acts as an 
indirect phospholipase A2 inhibitor, among other putative functions [26]. Collectively, all 
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of these processes aid in protection of epithelial cell integrity and thus homeostasis of the 
lung. 
As the inhaled air is cleansed of pathogens and harmful compounds by the 
discriminating landscape created by the conducting epithelium, it travels further into the 
lung where it reaches the terminal bronchioles and alveoli. The cellular composition in 
the alveoli consists of type I and type II pneumocytes, each with very distinct functions. 
Interestingly, type I cells comprise roughly 40% of the alveolar cell population, but due 
to their large surface area, they cover approximately 95% of the alveolar space. The 
primary function of type I cells is to facilitate efficient gas exchange to and from the 
blood, an ability made possible by their unique morphology and close contact to 
endothelial cells. In contrast, type II cells primarily secrete surfactant proteins and lipid 
mediators, such as dipalmitoylphosphatidylcholine (DPPC), which act to reduce alveolar 
surface tension, maintain alveolar shape and aid in innate immunity [27]. 
Because of the emerging data supporting the role of the epithelium in disease 
pathogenesis beyond simple barrier function, epithelial cells have become a central focus 
in understanding how immune responses are coordinated in the lung [28-30]. Airway 
epithelial cells can directly respond to inhaled allergens and toxins in part via pattern 
recognition receptors (PRR), such as toll-like receptors (TLR), which can recognize 
bacterial or viral components that penetrate the protective mucosal layer [31]. Upon 
ligand binding, TLRs can activate various transcription factors, including NFκB, leading 
to the induction of numerous genes involved in host defense and innate immunity [32]. 
As previously noted, the airway epithelium can produce cytokines that directly influence 
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the activation of innate immune cells in the lung, namely IL-25, IL-33 and TSLP. The 
epithelium can also indirectly contribute to the immune response by producing 
chemokines like KC, CCL20, MCP-1 and eotaxin, that act as chemotactic signals for 
neutrophils, dendritic cells, T-cells and eosinophils, respectively [33-36].  
 
In Vivo Models of Allergic Airway Disease 
Our understanding of the mechanisms involved in asthma pathogenesis has been 
formed through extensive research using animal models (Reviewed in [37]). To maintain 
focus, only mouse models of asthma will be considered in this review. In vivo models of 
allergic airways disease, including the conventional Ova protocol, have been broadly 
used to induce allergic airways disease in mice [38]; however, these models have also 
been subject to widespread criticism due to the method of antigen exposure and 
sensitization. In the Ova protocol, the antigen (Ova) is administered via intraperitoneal 
injection along with an adjuvant, Aluminum hydroxide, to elicit an immune response. 
The immune response observed in the Ova model is primarily T-helper 2 (Th2), with 
characteristic eosinophilic influx and little to no neutrophils [28]. By avoiding 
sensitization via the airways, the Ova protocol omits a crucial step in the immune 
cascade, namely recognition of inhaled substances by the airway epithelium. Other 
models are currently being employed to recreate a more representative asthmatic 
phenotype, in which a mixed eosinophilic and neutrophilic response is observed. 
Modified protocols involve direct sensitization of the airways, such as the LPS/ova 
protocol, in which a mixed Th2 and Th17 response associated with a neutrophilic influx 
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and steroid resistance has been noted [39]. Again, this model demonstrates promising 
results, but lacks in administration of an allergen in a physiologically relevant manner. 
More important still is a model in which a ubiquitous allergen that elicits immune 
responses in humans can also be used to evoke similar immune responses in animal 
models. The aeroallergen house dust mite (HDM; Dermatophagoides sp.), to which an 
estimated 85% of asthmatics are allergic, is one of the most common aeroallergens in 
nature [40]. HDM contains various immunogenic epitopes, TLR agonists and other 
substances that enhance its allergenicity [40]. In a mouse model utilizing HDM, the 
allergic inflammation observed was largely dependent on recognition by epithelial cells, 
particularly through the pattern recognition receptor, TLR4, which recognizes bacterial 
lipopolysaccharide (LPS) [31]. Furthermore, it has also been demonstrated that epithelial 
expression of the C-type lectin, dectin-1, which recognizes fungal β-glucan found on 
HDM, is a major factor in driving innate immunity [34]. These data indicate that the 




 The Interleukin-17 (IL-17) family of cytokines has recently received much 
attention in the area of inflammation and host defense, due in part to the discovery of the 
recently described Th17 cell [11, 41]. The hallmark cytokine of the Th17 cell is the 
potent elicitor of inflammatory responses, IL-17A. The receptors for IL-17A, IL-17RA 
and IL-17RC, are expressed ubiquitously in both mouse and man, including in the airway 
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epithelium [42]. Stimulation of epithelial cells with IL-17A leads to the 
TRAF6-dependent activation of NF-κB [43], and induction of genes important in 
downstream inflammatory responses, including IL-6 [44], GM-CSF [45], KC [7] and 
CCL20 [46], among others. In response to IL-17A, epithelial cells also express genes 
important in host defense against live pathogens, such as S100 proteins [47] and 
defensins [48]. When activated, the IL-17R complex can also signal via a 
TRAF5-dependent, TRAF6-independent manner, which results in the prolonged half-life 
of certain chemokine mRNAs, such as KC, thus leading to a protracted inflammatory 
response [49]. There is now evidence that epithelial cells can produce another IL-17 
family member, IL-17C, which signals in an autocrine manner to promote inflammation 
similar to that induced by IL-17A/F signaling [50]. The receptor for IL-17C, IL-17RE, 
was shown to be most highly expressed in mucosal organs, including the trachea and 
lungs, and more specifically was found on cells of epithelial origin [50, 51]. 
A crucial role for IL-17A has been demonstrated in a plethora of disease models, 
mainly those involved in host defense against foreign pathogens. In many instances, 
however, IL-17 signaling can go awry leading to the pathogenesis and exacerbation of 
several autoimmune and inflammatory diseases including rheumatoid arthritis, multiple 
sclerosis, psoriasis, systemic lupus erythematosus and asthma [52-56]. In asthma, 
aberrant IL-17A signaling has been shown to drive airway hyperresponsiveness in a 
mouse model by enhancing IL-13 driven disease [57]. Typically, IL-17A levels in 
asthmatics have been correlated to disease severity and often linked to steroid resistant 
asthma. This link with severe asthma is at least partially due to the ability of IL-17A to 
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stimulate the production of neutrophil chemoattractants, in particular KC and G-CSF, as 
many patients presenting with a severe type of asthma often have abundant airway 
neutrophils [39, 58]. Prognostic markers have included IL-17A levels in the serum of 
asthmatics, which appear to be an indicator of severe asthma [9, 10, 59]. 
IL-17 signaling has also been implicated in the development of fibrosis, as 
blockade of IL-17A signaling led to resolution of both inflammation and fibrosis in the 
lungs of mice [60]. In the setting of experimental hypersensitivity pneumonitis, a disease 
in which repeated exposure to inhaled organic antigens results in inflammation and 
fibrosis, IL-17A also plays a central role in driving fibrosis, which is dependent upon 
recruitment of neutrophils to the airways [61].  This indicates a potential link between 
IL-17A, severe asthma and neutrophil recruitment which may lead to constant tissue 
damage and regeneration, ultimately resulting in airway remodeling. 
 
Airway Remodeling 
Airway remodeling is described as the structural alterations of the airways that 
occur following chronic injury and repair. Characteristics of remodeling include (1) 
goblet cell hyperplasia and mucus metaplasia; (2) increased smooth muscle mass, 
indicated by elevated αSMA; (3) release of angiogenic factors and vascular expansion; 
and (4) increased subepithelial collagen deposition (Fig. 1) [62]. Although the processes 
involved in airway remodeling in asthmatics remain poorly understood, the resultant 
changes ultimately contribute to the clinical symptoms observed in lung dysfunction. 
Disruption of the epithelial layer, including death of ciliated cells, goblet cell hyperplasia 
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and increased release of growth factors, such as TGFβ, are thought to create an 
environment that promotes irreversible structural changes to the airways [63-65]. This 
injurious phenotype is due in part to chronic inflammation, although the extent of the 
contribution of inflammation remains unclear [66]. Others have demonstrated that 
allergen- or methacholine-induced bronchoconstriction alone can lead to airway 
remodeling in asthmatic patients, specifically by increasing collagen production and 
mucus metaplasia [67], further illustrating the complex and heterogeneous nature of the 
disease. 
Mucus metaplasia is the overproduction of mucus in the airways that can lead to 
airway obstruction and symptoms common of asthma. The type 2 cytokine, IL-13, has 
been shown to drive mucus production from the epithelium, promote fibrosis, induce 
AHR and is critical in the pathogenesis of asthma [68, 69]. In vitro culture of airway 
epithelial cells with IL-13 results in increased positivity of mucus staining and increased 
Muc5AC message, but following removal of IL-13 from culture, goblet cell metaplasia is 
reversed and ciliated epithelial cells repopulate the culture [70]. In mice administered the 
antigen Ova, distal airways were less susceptible to IL-13-induced mucus metaplasia, 
likely owing to lower expression of IL-13Rα1 [71]. IL-13 induces expression of Muc5AC 
and Gob5 from epithelial cells via JAK/STAT6-dependent signaling and direct 
administration of IL-13 into the airways of mice results in robust induction of both 
Muc5AC and Gob5 [72]. This IL-13-dependent induction was not observed in mice 
systemically lacking STAT6, indicating a specific mechanism for IL-13-induced mucus 
production [72]. Therapeutic inhibition of STAT6 signaling is therefore being touted as a 
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viable treatment option for certain subsets of asthmatics [73]. Interestingly, this therapy 
may not be useful in patients expressing high levels of IL-17A, which can induce mucus 
metaplasia independent of STAT6 signaling, bypassing any benefit potentially seen by 
STAT6 or IL-13 blockade [74]. These data illustrate the difficulties associated with 
creating a single therapeutic to encompass all asthmatics and point to the need for 
development of more targeted individual therapies. 
A layer of smooth muscle resides around the airway epithelium and aids in 
contraction and relaxation of the airways. In asthmatics, the thickness of the airway 
smooth muscle (ASM) layer is increased, reportedly due to both ASM hyperplasia and 
hypertrophy [75-78]. This is of clinical relevance, as an enlarged ASM layer can 
contribute to symptoms of asthma. In a mouse model, hypertrophic ASM was shown to 
positively correlate with AHR, particularly central airway resistance, following chronic 
exposure to the antigen Ova [79]. Furthermore, acute exposure of mice to Ova did not 
lead to a correlation between increases ASM mass and AHR, but did result in active 
proliferation of ASM [79]. This indicates that prolonged exposure to an allergen/antigen 
evokes an immune response that can thus amplify ASM proliferation. Recent evidence 
demonstrates that human ASM cells can recognize and subsequently proliferate in 
response to IgE, increasing ASM mass [80]. This amplification loop may be dysregulated 
in certain subsets of asthma, including severe asthma that is often refractory to treatment 
with corticosteroids. Adding to the complexity, certain chemokines such as eotaxin, 
RANTES and IL-8, typically involved in the recruitment of immune and inflammatory 
cells, appear to induce ASM cell proliferation and survival [81]. Commonly associated 
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with fibrosis, transforming growth factor beta (TGFβ) has also been implicated in ASM 
hyperplasia, although the role of TGFβ in ASM hyperplasia still remains controversial 
and context-dependent [82]. 
TGFβ is front and center in many fibrotic diseases and plays an active role in 
structural alterations observed in airway remodeling. In fact, TGFβ expression tends to 
correlate with collagen levels and is further enhanced with increasing asthma severity 
[83]. Therefore, in settings of lung remodeling and fibrosis, targeting TGFβ signaling or 
upstream mediators of TGFβ production has been a central avenue for therapeutic 
development [84]. Therapies directed at inhibition of IL-13 signaling (described above), 
may have impacts beyond ASM mass. In addition to increasing ASM mass, IL-13 can 
also increase levels of active TGFβ and matrix metalloproteinase 2 (MMP2), driving 
expression of type 1 collagen and contributing to subepithelial fibrosis in asthma [85]. 
Another recently discovered player in fibrotic remodeling is periostin, originally thought 
to be an adhesion molecule with the ability to bind matrix proteins and contribute to 
subepithelial fibrosis [86]. Periostin was initially considered to be limited to 
mesenchymal cells, but further investigation revealed that bronchial epithelial cells 
produce periostin in response to IL-13 and stimulate TGFβ signaling and collagen 
production from fibroblasts [87]. Interestingly, incubation of recombinant periostin with 
type 1 collagen resulted in increased elastic modulus, expanding its role beyond simply 
binding to matrix proteins, but also actively modifying the matrix itself [87]. Clinically, a 
correlation has been noted between levels of periostin and AHR in asthmatic children, 
leading to a potential new therapeutic target other than TGFβ for fibrotic remodeling 
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[88]. Novel therapeutics directed at targets upstream of TGFβ or IL-13 signaling may 
offer new avenues for therapeutic intervention and treatment of severe forms of asthma 
accompanied by abundant remodeling. 
Another common manifestation of remodeling is production of angiogenic factors 
leading to increased number of blood vessels surrounding the airways. In fact, elevated 
vascular endothelial growth factor (VEGF), a potent mediator of angiogenesis produced 
by cells via hypoxia inducible factor (HIF) transcription factors [89], has been observed 
in asthmatic airways [90] and has been associated with exacerbation of asthma [91]. 
More importantly, epithelial-derived VEGF has been shown to enhance antigen 
sensitization in the lungs and drive Th2-associated inflammation, partially through down-
regulation of micro-RNA (miR)-1 expression in the lung [92, 93]. Despite advancements 
in our understanding of mechanisms involved in various aspects of airway remodeling, 
the clinical impact of vascular remodeling is still largely unknown [94]. It is possible that 
infiltrating immune and inflammatory cells trafficked into the airways via newly formed 
blood vessels may contribute to vascular remodeling by production of damaging 
cytokines, but there is a paucity of evidence to support this. Crosstalk between structural 
cells and immune/inflammatory cells appears to be a major contributing factor [94], but 
large gaps in our understanding of the clinical implications of vascular remodeling 
prevent any firm conclusions as to its direct impact on disease. Regardless, it is clear that 
factors involved in vascular remodeling are a valuable consideration in the development 





 According to both the European Respiratory Society and the American Thoracic 
Society, severe asthma is loosely defined as asthma that requires high doses of inhaled 
corticosteroids (ICS) in conjunction with other treatments, including systemic 
corticosteroids, to control potential exacerbations [95]. Severe asthmatics represent only a 
fraction of those afflicted with asthma, but account for nearly 80% of annual healthcare 
costs [96]. Therefore, development of novel therapeutics for targeting severe asthma has 
been a large focus in the field of asthma research. In certain subsets of severe asthmatics, 
patients are unresponsive to corticosteroid treatment, offering even fewer avenues 
available for symptom management. Although the precise mechanisms leading to severe 
asthma remain unidentified, severity of the disease tends to correlate with some key 
markers, including increased levels of IL-17A and presence of IL-17A-producing cells 
[97]. It should be noted, however, that the pathogenic role of IL-17A in asthma appears to 
vary greatly depending on the patient subpopulation [98]. Thus, while IL-17A is often a 
useful predictor of asthma severity, several other factors can contribute to drive a more 
severe phenotype. Options for disease management continue to evolve, as is evidenced by 
many newly developed therapeutics that show some promise in asthmatics (Reviewed in 
[99]).  
Typical treatment regimens include a combination of ICS and a β2-agonist, which 
works well for managing mild or moderate asthma [100]. Additionally, leukotriene 
receptor antagonists (LTRA) have also been used in conjunction with ICS, but no further 
benefit has been observed by this addition beyond what would be seen simply by 
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increasing the ICS dose [101]. These typical treatment regimens often fail to completely 
resolve asthmatic episodes in severe asthmatics; thus, clinicians and researchers alike 
continue to search for an effective therapy. Certain invasive methods are also being 
employed in severe asthmatics with some promise. One such method is bronchial 
thermoplasty, which utilizes radio frequencies to briefly heat the surrounding airway to 
roughly 65
o
C, destroying some of the underlying smooth muscle [102]. This therapy was 
first approved by the FDA in 2010, and has been used with some success. Unlike therapy 
using biologics, there is no need for sustained treatment and results are often seen within 
weeks [102]. This offers a promising therapeutic avenue for severe asthmatics that do not 
respond effectively to ICS or other treatment regimens. 
 
Nuclear Factor-kappa B 
NF-κB Signaling: Classical and Alternative Pathways 
 Nuclear factor-kappa B (NF-κB) is a transcription factor that is a central regulator 
of immune and inflammatory responses and also plays an important role in promoting 
cell survival and proliferation. The NF-κB pathway is present in almost every animal cell 
and is involved in transducing signals from numerous ligands [103, 104]. Because of its 
central role in modulating immune responses, aberrant NF-κB signaling is frequently 
implicated in the pathogenesis of several diseases, including asthma. Thus far, two arms 
of the NF-κB pathway have been described, aptly named classical and alternative, each 
consisting of unique players involved in signal transduction. The classical pathway 
consists primarily of the transcription factors RelA (p65) and p50, which are held inactive 
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in the cytosol by inhibitory IκB proteins under resting conditions (Fig. 2). Stimulation 
with a ligand, such as LPS or IL-17A, leads to assembly of adaptor proteins, such as 
TRAF6, and phosphorylation of the effector kinase TAK1. Critical for proper NF-κB 
signal transduction, TAK1 can then associate with the heterotrimeric IKK signalsome 
consisting of IKKβ, IKKα and NEMO (IKKγ), phosphorylating IKKβ [105]. This in turn 
leads to the phosphorylation and subsequent ubiquitination of IκBα, which is then 
degraded by the 26S proteasome, allowing nuclear entry of RelA/p50 and downstream 
gene induction. Genes induced by the classical NF-κB pathway have been associated 
with inflammation and immunity, and deregulation of this pathway can lead to a variety 
of diseases, including cancer and inflammatory/immune disorders.  
The alternative pathway relies primarily on the transcription factors RelB and p52 
and is associated with discrete cellular functions unique from classical NF-κB signaling. 
Activation of the alternative pathway is dependent on the activity of NF-κB-inducing 
kinase (NIK), which is constantly ubiquitinated by TRAF3 and signaled for degradation 
under resting conditions. Following stimulation with a unique set of ligands, TRAF3 
itself is ubiquitinated and degraded, allowing for NIK to phosphorylate a homodimeric 
IKKα complex, independent of IKKβ and NEMO, which can then phosphorylate p100. 
P100 is typically bound to RelB, sequestering it to the cytosol and preventing nuclear 
entry. Phosphorylation of p100 at several serines in both the C and N termini by IKKα 
leads to p100 processing by the 26S proteasome to form p52, allowing RelB/p52 dimers 
to enter the nucleus [106, 107]. The alternative pathway has generally been studied in 
cells of the immune system and in the context of lymphoid organogenesis. Until recently, 
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it was widely accepted that these two pathways existed independently with little 
crosstalk, leading to unique transcriptional profiles. However, a recent publication by our 
group demonstrated that in fact both pathways cooperate extensively to control NF-κB 
activation and downstream gene induction in lung epithelial cells in response to a variety 
of stimuli [108]. This aids in expanding the role of alternative NF-κB to structural cells 
and demonstrating a more complex relationship between the classical and alternative 
NF-κB pathways than was previously known. 
 
NF-κB Regulation 
Being such a pivotal regulator of immune responses, NF-κB family members are 
subject to extensive regulation through various post-translational modifications (PTMs). 
These include phosphorylation, ubiquitination, acetylation as well as oxidant dependent 
PTMs, including S-nitrosylation and S-glutathionylation. Depending on the target 
protein, these modifications can either activate or inhibit NF-κB signaling, thus affecting 
subsequent downstream signaling events. Important to this body of work are the oxidant-
dependent PTMs, in particular S-glutathionylation, the conjugation of glutathione with 
reactive cysteines, which will be discussed in greater detail later. Several targets of the 
NF-κB pathway have been shown to be targets for S-glutathionylation, including RelA, 
IKKβ, p50, IκBα and IKKα [109-113]. S-glutathionylation of these proteins confers 
inhibition of the NF-κB pathway, suppressing downstream proinflammatory gene 
induction. Our group has also demonstrated that the glutathionylation of IKKβ and IKKα 
are dependent on the activity of the enzyme glutaredoxin 1 (Glrx1) [110, 113], which, 
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under physiological conditions, can deglutathionylate target proteins and restore their 
function. In settings of disease where there is increased oxidative stress, it may also 
follow that there are high levels of oxidized cysteines on proteins that may be targeted for 
S-glutathionylation, a topic covered in greater detail in the following section. 
 
Redox Biology and Cysteine Oxidation 
Endogenous Sources of Oxidants 
 Oxidants, such as hydrogen peroxide, are widely accepted to be involved in the 
pathogenesis of various chronic inflammatory diseases, including asthma. Despite 
recognition of this fact, the exact source of the oxidants involved in disease pathogenesis 
and mechanisms of their pathogenic action remain largely enigmatic. Both endogenous 
(e.g. mitochondrial respiration) as well as exogenous (e.g. environmental allergens) 
sources of oxidants exist, and the differential or synergistic impact of oxidants on disease 
pathogenesis based on their source is unknown. At the cellular level, several key sources 
of oxidants exist: namely enzymes that produce reactive oxygen species (ROS) like H2O2 
and those that produce reactive nitrogen species (RNS) like NO. Endogenous H2O2 is 
produced in large part by members of the NADPH oxidase (NOX) family of enzymes. 
Members include NOX1, NOX2, NOX3, NOX4 & NOX5 and dual oxidase 1 (DUOX1) 
and DUOX2. These enzymes exist as membrane-bound multi-subunit complexes that 
transfer electrons from NADPH to molecular oxygen to produce the ROS superoxide 
(O2
-
), which can be further reduced to form H2O2 [114]. NOX4 is unique from other 
NOXs or DUOXs in that it is constitutively active, leading to speculation that its activity 
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is regulated primarily at the level of transcription [115]. Another interesting characteristic 
of NOX4 is its apparent ability to produce H2O2 directly [116], though this still remains 
controversial, as others report the major ROS produced by NOX4 to be O2
-
 [117, 118]. 
DUOX1 and DUOX2 are the only other members of this family known to directly 
produce H2O2, a function demonstrated to have great importance in airway mucosal host 
defense [119-121]. In either case, NOX members have been implicated in a variety of 
lung diseases, including asthma and cancer, providing strong evidence linking aberrant 
oxidant production with disease pathogenesis [122-124]. 
NO is mainly produced by nitric oxide synthase (NOS) enzymes, of which there 
are three known forms in mammals: neuronal NOS (nNOS; NOS1), inducible NOS 
(iNOS; NOS2) and endothelial NOS (eNOS; NOS3). The amino acid arginine is used as 
the substrate by NOS to produce one molecule of NO and the byproduct citrulline. The 
NO produced in this reaction acts as a vasodilator and a bronchodilator, in part by the 
activation of guanylate cyclase and resultant production of cGMP, and is thus important 
for maintaining proper airway function [125]. Alternatively, NOS-derived NO can readily 
react with O2
-
 to form the RNS peroxynitrite (ONOO
-
) and with the antioxidant tripeptide 
glutathione (GSH), to form the S-nitrosothiol, S-nitrosoglutathione (GSNO). Because NO 
readily reacts with other species, NO signaling is also believed to function via S-
nitrosylation of proteins which can have drastic impacts on protein function [126]. It is 
known that GSNO is a potent bronchodilator, the concentrations of which are higher in 
the airways than NO itself [127]. GSNO was also shown to be depleted in the airways of 
asthmatics, and a study using an experimental asthma model determined that increased 
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GSNO reductase (GSNOR) is primarily responsible for the removal of GSNO and protein 
SNO, leading to more hyperresponsiveness following allergen challenge [128], 
implicating a protective role for SNO. 
Both in vitro and in vivo studies demonstrated that the addition of ONOO
-
 is 
sufficient to drive hyperresponsiveness and damaging inflammation in guinea pigs [129] 
and abundant NO production has been observed in asthmatic patients, potentially leading 
to enhanced production of ONOO
-
 and subsequent damage [130, 131]. GSNO reductase 
(GSNOR) polymorphisms have been associated with the pathogenesis of asthma [132] 
and restoration of the GSNO pool via pharmacological inhibition of GSNOR was 
recently shown to be protective in a mouse model of allergic airways disease [133]. 
Elevated NOS activity is also observed in inflammatory lung diseases, and iNOS was 
shown to be critical in driving allergen-induced acute inflammation, as well as fibrotic 
remodeling, but not chronic inflammation [134], further illustrating the complexity of 
mechanisms in which oxidants contribute to disease. 
It is now becoming recognized that oxidants control pathobiological functions 
following their compartmentalized production, including the mitochondria and 
endoplasmic reticulum (ER). As a byproduct of cellular metabolism, the mitochondrial 
electron transport chain leaks electrons which can then react with molecular oxygen to 
produce superoxide and eventually H2O2 [135]. Superoxide dismutase 2 (SOD2 or 
MnSOD), located in the mitochondrial matrix, is mainly responsible for converting 
harmful O2
-
 into H2O2 and oxygen. From here, H2O2 can cross the mitochondrial 
membrane into the cytosol, where it can act locally as a second messenger in part via 
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oxidation of protein cysteines. The ER is also an important source of oxidants, 
particularly when undergoing the unfolded-protein response (UPR), in which abundant 
H2O2 is produced due to the refolding of proteins [136]. Much of the H2O2 produced is a 
consequence of disulfide bond isomerization, a process in which reduced protein 
disulfide isomerases (PDI) are oxidized and subsequently regenerated by ER 
oxidoreductase 1 (Ero1), generating H2O2 in the process. Excess H2O2 is often removed 
by the ER resident peroxiredoxin IV (Prx4), preventing rampant oxidative damage to 
properly folded proteins [137]. Partly derived from the ER, peroxisomes are responsible 
for carrying out important redox reactions and are therefore a major site of oxidant 
production. Long chain fatty acid catabolism can produce H2O2 as a byproduct, and this 
can be removed via peroxisomal catalase. Because of the ability of peroxisomes to make 
excess H2O2, their contribution to oxidative stress is becoming more widely appreciated 
[138]. 
Inflammatory cells are important in defense against pathogens, but in some cases, 
excess production of oxidants by these cells is thought to be pathogenic. Certain 
specialized cell types, neutrophils and eosinophils in particular, produce copious amounts 
of oxidants in response to pathogens or inflammatory signals. Neutrophil 
myeloperoxidase (MPO) can utilize H2O2 and chloride anion (Cl
-
) to produce 
hypochlorous acid (HOCl, bleach) and can also oxidize tyrosine residues to tyrosyl 
radicals using H2O2 [139]. Both HOCl and tyrosyl radicals are highly cytotoxic and are 
therefore used for killing bacteria or other invading pathogens during the respiratory 
burst. Eosinophils have a similar mechanism, utilizing eosinophil peroxidase (EPO), 
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which preferentially uses bromide anions (Br
-
) over chloride anions to form 
hypobromous acid (HOBr) [140, 141], also used to kill invading pathogens. Proteins 
themselves can also be halogenated by either chloride or bromide anions via diverse 
mechanisms, including halogenases, further affecting protein function [142, 143]. When 
production of oxidants becomes dysregulated, the resultant oxidative stress and 
subsequent reactive products are believed to contribute to the pathogenesis of various 
lung diseases, including asthma [144, 145]. 
 
Exogenous Sources of Oxidants 
 Exposure to exogenous pollutants or allergens can lead to an inflammatory 
response in the lung, accompanied by the production of endogenous oxidants. Some 
exogenous toxins, such as cigarette smoke, which contains numerous oxidants, and 
ozone, a strong oxidant itself, can robustly induce oxidant production in the lung [146-
148]. Increases in oxidative stress are also seen upon experimental exposure to other 
pollutants, including diesel exhaust and even man-made materials, such as carbon 
nanotubes [149, 150]. Although the lung is well-equipped to deal with oxidative flux with 
robust antioxidant systems in place, excess oxidant production is thought to contribute to 
tissue damage and chronic inflammation [151]. The ability of allergens to directly 
produce oxidants remains an active area of research, and has revealed some intriguing 
findings. As described earlier, among the most common allergens is house-dust mite 
(HDM), to which roughly 80% of asthmatics are allergic and which contains numerous 
antigenic proteins and pro-inflammatory compounds [40]. Although it has not been 
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determined if HDM contains any ROS-producing enzymes that affect their allergenicity, 
it is well-known that HDM can induce the production of oxidants in the airways and lead 
to inflammation [152]. Redox-related enzymes, such as Trx, are also important in 
controlling cellular responses to the oxidants induced by HDM [153]. In contrast, pollen 
from several plant species, including ragweed, possess intrinsic NOX-like activity, 
directly contributing to the imbalanced redox environment and subsequent inflammation 
in the airways via the production of  H2O2 [154]. It is thought that the oxidant signal 
produced by pollen NOX enhances the subsequent inflammatory response to the pollen 
allergens [155]. Other allergens, such as the fungus Alternaria alternata (A. alternata), 
also have NOX-like enzymatic activity [156, 157]. This NOX-like-mediated production 
of H2O2 has been primarily studied in the plant pathology field and has not been 
investigated in the setting of human lung diseases caused by A. alternata. If NOX activity 
in A. alternata is comparable to that seen in ragweed pollen, similar downstream impacts 




The field of redox biology has advanced rapidly over the past several decades and 
has enhanced our understanding of the complex cellular mechanisms involved in 
managing oxidative stress. Although large amounts of oxidants can be damaging to cells 
(oxidative stress), it is now appreciated that low levels of oxidants such as H2O2 and NO 
are important in homeostatic functions (redox biology), but also potentially in signaling 
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cascades that contribute to disease (redox pathobiology). It is clear that a highly complex 
network of oxidant-dependent signaling exists within the lungs. Arguably one of the most 
important mechanisms of transducing oxidant dependent signals is through the amino 
acid cysteine (Cys, C) due to its sulfhydryl side chain (SH). Only certain cysteine 
residues have been denoted as ‘reactive’, meaning they can be readily oxidized, reduced 
and otherwise modified.  
Reactive cysteines are normally characterized as having a lower pKa than that 
typical of cysteine (≤7 for reactive cysteine; 8-8.5 for normal cysteine). This 
microenvironment favors the loss of a proton from the SH group of cysteine, forming a 
thiolate anion (S
-
) which can then be oxidized to sulfenic acid (SOH), the initial oxidation 
product of cysteine [158]. Large-scale efforts to determine reactive cysteine residues have 
been undertaken, including the use of proteomics and computer modeling programs. 
Providing us with a useful tool for prediction, computer algorithms have had some 
success in determining reactivity of cysteines and thus potential redox targets [159, 160]. 
Proteomics have also been used to mine for reactive cysteine residues in proteins. 
Methods now use isotope-coded affinity tag (ICAT) reagents combined with mass 
spectrometry to directly compare two samples simultaneously, allowing determination of 
reactive cysteine residue [161-163]. These collective efforts have helped develop 
methods for the determination of reactive cysteine residues, but the next even more 
challenging step is to resolve the oxidation end-product that exerts its influence on the 
protein of interest. 
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Cysteine modifications vary, but all generally rely on the ability of the SH group 
of cysteine to be oxidized to SOH (Fig. 3). From here, SOH can be further irreversibly 
oxidized to sulfinic acid (SO2H) and eventually sulfonic acid (SO3H) in the presence of 
an oxidant, such as H2O2. Interestingly, the SO2H form of cysteine is largely irreversible, 
leading to degradation, but there is one known case where the hyperoxidized (SO2H) 
forms of peroxiredoxin I-IV (PrxI-IV) can be enzymatically reduced by sulfiredoxin 
(Srx) [164]. There is no known mechanism by which the SO3H form of cysteine can be 
reduced, and this oxidation typically leads to degradation. Under certain circumstances, 
reactive cysteine can be conjugated to other molecules, such as GSH or NO, to form S-
glutathionylated (SSG) or S-nitrosylated (SNO) proteins, respectively. These represent 
two well-studied redox-dependent post-translational modifications of cysteine and have 
been shown to play critical roles in redox regulation of protein function, launching a 
unique area of research [126, 165]. These modifications are thought in part to protect 
proteins from further irreversible oxidation, but also regulate protein function and 
signaling. SNO is the reversible, covalent conjugation of NO to a reactive cysteine in a 
protein that occurs without aid of enzymatic catalysis, whereas the reverse reaction can 
be catalyzed enzymatically via GSNOR, as well as Trx [166, 167]. Surfactant protein D 
is also a target for SNO in the lung, which enhances its pro-inflammatory function by 
allowing its binding to receptors, activating downstream NF-κB [168]. These examples 





S-glutathionylation and Glutaredoxin 
S-glutathionylation (SSG) represents the covalent and reversible addition of GSH 
to reactive cysteine in proteins. SSG can occur spontaneously, in which oxidized GSH 
(GSSG) reacts with cysteine residues, leading to a glutathionylated protein. Unlike SNO, 
there is evidence that SSG can be catalyzed enzymatically, specifically by glutathione S 
transferase Pi (GSTP) [169] and to some extent GSTM, though the latter has not been 
shown to induce SSG in a biological setting [170]. While an exhaustive list of GSTP 
substrates for SSG has not been established, it is likely that several targets exist for this 
enzyme and others in the GST family. Interestingly, GSTO1, another member of the GST 
family, has been implicated in catalyzing the reverse reaction, acting as a 
deglutathionylating enzyme [171]. To date, numerous targets of SSG have been 
determined and studied in detail, including transcription factors, kinases, structural 
proteins and enzymes involved in metabolism [172, 173]. The reversible conjugation of 
GSH to protein cysteine can have profound impacts on signaling, as it alters the shape, 
charge and size of the target protein in question. Depending on the protein, SSG can 
either activate or inhibit its function. Specifically, our group has shown that SSG of 
NF-κB proteins leads to dampened NF-κB activity and decreased production of 
downstream inflammatory mediators, and this modification appears to be dependent upon 
the enzyme glutaredoxin 1 (Glrx1) [110, 113]. Glrxs are the main deglutathionylating 
enzymes in mammalian systems [174, 175], although other enzymes can also perform 
this reaction under certain conditions, including sulfiredoxin [176].  
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 Glrxs are part of the larger thioredoxin fold family of enzymes which includes 
oxidoreductases, as well as other enzymes with diverse functions [177], as will be further 
discussed in the following sections.  All oxidoreductases in this family share a highly 
conserved active site consisting of the motif CXXC or CXXS, involved in reducing 
disulfide bonds (S-S) or other oxidized cysteine and in some cases, reversing 
glutathionylated proteins [178]. In mammalian cells, there are at least four known Glrxs: 
Glrx1 (cytosolic), Glrx2 (mitochondrial/nuclear), Glrx3/PICOT (cytosolic) and Glrx5 
(mitochondrial). The most well-studied of these are Glrx1 and Glrx2. Mitochondrial 
Glrx5 is primarily involved in [2Fe-2S] cluster maturation and transfer from scaffold 
proteins to their targets [179], a key mechanism in cellular iron regulation. PKC-
interacting cousin of thioredoxin (PICOT), also known as Glrx3, was first discovered as a 
negative regulator of c-Jun N-terminal kinase (JNK) and NF-κB pathways via its Trx-like 
domain interaction with protein kinase C [180]. PICOT is unique in that it contains two 
CGFS motifs in its active site, highly conserved between plants and animals. Glrx1 and 
Glrx2 are very similar in function in that they are both very selective for 
deglutathionylation reactions, but Glrx2 displays a lower efficiency for catalyzing this 
reaction due to its increased active site cysteine pKa [181]. Glrx2 is primarily localized in 
the mitochondrial matrix and is involved in regulating the redox environment by 
controlling SSG of protein thiols within the mitochondria. Specifically, Glrx2 can 
deglutathionylate various targets in the mitochondrial inner membrane, including 
complex I of the electron transport chain [182, 183]. In mouse lens epithelial cells 
isolated from Glrx2-deficient mice, elevated oxidative stress and increased mitochondrial 
29 
 
glutathionylated proteins were observed, further demonstrating a specific, localized role 
of Glrx2 in maintaining mitochondrial redox balance [184].  
 The most extensively characterized isoform of the Glrx family is Glrx1. A 
primary role for Glrx1 is deglutathionylation of target proteins, several of which have 
been reported to date [109-111, 113, 185, 186]. Interestingly, Glrx1 is much more 
efficient at deglutathionylating proteins compared to other related enzymes [175]. 
Although primarily considered a cytosolic enzyme, studies have reported Glrx1 in the 
nucleus [187] and in the mitochondrial intermembrane space [188]. Its localization to the 
intermembrane space of the mitochondria is distinct from that of Glrx2, likely leading to 
control of diverse mitochondrial functions, including redox regulation of apoptosis [188]. 
Interestingly, Glrx1 has been detected in serum from healthy human donors, providing 
evidence that Glrx1 can be secreted, although the specific cell-type or types responsible 
remain unknown [189]. Further reports demonstrate secretion of thioredoxins (Trxs), 
peroxiredoxins (Prxs) and other Glrxs from myoblasts, which may be one cell type 
responsible for detectable serum levels in vivo [190]. Glrx1, like other Trx-fold members, 
lacks a typical cellular export signal, and when one group investigated the potential role 
of exosomal export of these enzymes, the results showed no detectable levels in the 
exosome fraction, but rather in the supernatant, leading to further questions about the 
mechanism of export and what the extracellular functions may be [190].  
Membrane-bound Trx has been shown to act at the epithelial cell surface to 
reduce disulfide bonds in extracellular β-defensin 1, a cytotoxic peptide produced by 
neutrophils, enhancing its bactericidal potency [191, 192]. Another redox enzyme, 
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quiescin sulfhydryl oxidase 1 (QSOX1), was demonstrated to possess extracellular 
activity, being necessary for the proper incorporation of laminin into the extracellular 
matrix deposited by fibroblasts [193]. Interestingly, this study also showed that matrix 
deposited in the absence of QSOX1 was defective in promoting cell adhesion, pointing to 
the importance of cysteine redox status in this process. No such activities have been 
demonstrated thus far for Glrx1, but detection of Glrx1 protein in the sputum of 
asthmatics [194] may indicate a potential role for modifying extracellular proteins in the 
airway lumen or in the extracellular matrix, similar to functions described above for 
QSOX1. 
 
Glutaredoxin in Asthma 
 Abundant evidence has established that an altered redox environment is a 
contributing force to the development of asthma. More specifically, data from our 
laboratory suggests a potential role for Glrx1 in maintaining the redox balance in the lung 
in both mouse models [195, 196] and in asthmatic patients [194]. In human subjects, 
elevated sputum Glrx1 and decreased SSG were associated with impaired lung function, 
indicating a possible negative role for Glrx1 [194]. Interpretation of the limited clinical 
data is at best speculative, as it is unknown if alterations in Glrx1 and SSG content are 
causative or simply a consequence of the increased oxidative environment in these lungs. 
In response to allergen challenge, Glrx1 protein in the lung has been shown to increase 
and Glrx1-/- mice in the Balb/C background displayed enhanced resolution of airway 
hyperresponsiveness (AHR) following exposure to the antigen ovalbumin [196], further 
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suggesting a negative correlation between Glrx1 and lung function. Despite these efforts, 
the precise function of Glrx1 in disease pathogenesis is still not well understood and may 
include both intracellular and extracellular functions, some of which remain to be 
discovered. 
 
Statement of Hypothesis and Scope of Thesis 
 As outlined in the literature review, perturbation of the cellular redox balance is 
becoming widely appreciated as a contributing factor driving the pathogenesis of various 
diseases, including asthma. S-glutathionylation of reactive cysteines has emerged as a 
major modification that affects a variety of signaling pathways, including NF-κB, due in 
large part to the existence of glutaredoxins (Glrx), namely Glrx1, which specifically 
regulate this process. There exists a paucity of data supporting a role for Glrx1 in animal 
models of allergic airway disease which utilize asthma-relevant allergens and even less 
data showing a role for Glrx1 in asthmatic populations. For that reason, we hypothesized 
that exposure of lung epithelial cells to IL-17A results in an altered cellular redox balance 
contributing to enhanced S-glutathionylation of NF-κB proteins and Glrx1 controls the 
extent of IL-17A-induced S-glutathionylation. Additionally, we hypothesized that Glrx1 
status controls the extent of allergen-induced airway remodeling in a house dust mite 
model of allergic airway disease. 
 The goal of Chapter 2 was to determine whether Il-17A stimulation of lung 
epithelial cells leads to enhanced oxidative stress and a resultant environment conducive 
to protein S-glutathionylation. Furthermore, we sought to establish a role for the 
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Glrx1/S-glutathionylation axis in controlling epithelial activation of NF-κB and 
downstream gene induction. We also investigated the importance of IKKα status in lung 
epithelial cell responses to IL-17A via analysis of downstream pro-inflammatory gene 
expression. 
 In Chapter 3 of this thesis, we sought to explore the in vivo role of Glrx1 in 
settings of house dust mite (HDM)-induced allergic airway disease. To do so, we utilized 
two complementary approaches: a knockout mouse that globally lacks the Glrx1 gene and 
a transgenic approach in which Glrx1 is inducibly overexpressed in CCSP-positive lung 
epithelial cells.  This allowed us to evaluate the impact of Glrx1 absence or increased 
expression on parameters of airway hyperresponsiveness, inflammation and airway 
remodeling following HDM exposure. We also utilized Glrx1-targeted siRNA or 
epithelial cells isolated from Glrx1
-/-
 mice to assess the impact of Glrx1 on epithelial and 
mesenchymal markers in response to HDM and TGFβ. 
 Lastly, in Chapter 4 we discuss the impact of the findings obtained from these 
studies and offer insight into the role that Glrx1 plays in the pathogenesis of allergic 
airway disease. Furthermore, we discuss the possible role of Glrx1 in settings of human 
lung diseases, suggesting possible new targets that could be exploited in clinical settings 









Figure 1: Airway Epithelial Cells in Remodeling. Exposure of the lung epithelium to 
various stimuli, such as HDM, can damage the epithelial layer. This is normally resolved 
by mechanisms discussed in this thesis, resulting in a restored and functional epithelial 
layer. In cases of chronic injury, the injury/repair mechanism can become imbalanced, 
resulting in airway remodeling which includes mucus metaplasia, smooth muscle cell 
proliferation, excessive collagen production and secretion of VEGF, leading to vascular 
remodeling. This process can result in irreversible damage to the airways and is a 
frequently observed in settings of asthma. 
 
Figure 2: Schematic depicting classical and alternative NF-κB pathways. In the classical 
NF-κB pathway (left), activation by various stimuli results in phosphorylation of the 
upstream kinase IKKβ, which can then phosphorylate inhibitor of kappa B alpha (IκBα). 
Subsequent ubiquitination of IκBα marks it for degradation by the 26S proteasome, 
allowing the RelA/p50 heterdimer to enter the nucleus. In the alternative NF-κB pathway 
(right), activation begins with stabilization of NF-κB-inducing kinase (NIK), which 
phosphorylates IKKα. Activated IKKα can then phosphorylate p100, which leads to its 
subsequent ubiquitination and partial degradation by the 26S proteasome to the active 




Figure 3: Schematic depicting cysteine oxidations. Reactive cysteines can exist in the 
reduced thiol form (SH) or more reactive thiolate form (S
-
). After exposure to an oxidant, 
such as hydrogen peroxide (H2O2), the reactive cysteine can be oxidized to sulfenic acid 
(SOH). In the presence of abundant oxidants, the SOH form of cysteine can be further 
oxidized to sulfinic (SO2H) and sulfonic (SO3H) acids. The SO3H form is irreversible, 
resulting in permanent protein inactivation and usually degradation. The SO2H form, 
however, can be reduced in some instances (specified in the text) by sulfiredoxin (Srx). 
SOH forms of reactive cysteines are also thought to be the precursor step to S-
glutathionylation (PSSG), which can be catalyzed by glutathione S transferase Pi (GSTP) 
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IL-17RA: Interleukin-17 receptor A 
IL-17RC: Interleukin-17 receptor C 
IL-17RE: Interleukin-17 receptor E 
IL-22: Interleukin-22 
IgE: Immunoglobulin E 
Th1: T helper type 1 
Th2: T helper type 2 
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ILC3: Type 3 innate lymphoid cell 
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KC/CXCL1: Keratinocyte chemoattractant/ chemokine (C-X-C motif) ligand 1 
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PRR: Pattern recognition receptor 
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THE GLUTAREDOXIN/S-GLUTATHIONYLATION AXIS REGULATES INTERLEUKIN 17A-
INDUCED PRO-INFLAMMATORY RESPONSES IN LUNG EPITHELIAL CELLS IN ASSOCIATION 
WITH S-GLUTATHIONYLATION OF NUCLEAR FACTOR-ΚB FAMILY PROTEINS 
Abstract 
Interleukin-17A (IL-17A) is a newly emerging player in the pathogenesis of 
chronic lung diseases that amplifies inflammatory responses and promotes tissue 
remodeling. Stimulation of lung epithelial cells with IL-17A leads to activation of the 
transcription factor, nuclear factor kappa B (NF-κB), a key player in the orchestration of 
lung inflammation. We have previously demonstrated the importance of the redox-
dependent post-translational modification, S-glutathionylation, in limiting activation of 
NF-κB and downstream gene induction. Under physiological conditions, the enzyme 
glutaredoxin 1 (Grx1) acts to deglutathionylate NF-κB proteins, which restores functional 
activity. In this study, we sought to determine the impacts of S-glutathionylation on IL-
17A-induced NF-κB activation and expression of pro-inflammatory mediators. C10 
mouse lung alveolar epithelial cells, or primary mouse tracheal epithelial cells exposed to 
IL-17A show rapid activation of NF-κB, and the induction of pro-inflammatory genes. 
Upon IL-17A exposure, sulfenic acid formation and S-glutathionylated proteins 
increased. Assessment of S-glutathionylation of NF-κB pathway components revealed S-
glutathionylation of RelA (RelA-SSG) and inhibitory kappa B kinase alpha (IKKα-SSG) 
after stimulation with IL-17A. SiRNA-mediated ablation of Grx1 increased both RelA-
SSG and IKKα-SSG and acutely increased nuclear content of RelA, and tended to 
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decrease nuclear RelB. SiRNA mediated ablation or genetic ablation of Glrx1 decreased 
the expression of NF-κB regulated genes, KC and CCL20, in response to IL-17A, but 
conversely increased the expression of IL-6.  Lastly, siRNA-mediated ablation of IKKα 
attenuated nuclear RelA and RelB content and decreased expression of KC and CCL20 in 
response to IL-17A. Together, these data demonstrate a critical role for the S-
glutathionylation/Grx1 redox axis in regulating IKKα-SSG and the responsiveness of 



















The Interleukin-17 (IL-17) family is a newly emerging class of cytokines that 
plays a critical role in a variety of biological processes, including innate host defense and 
inflammation. This cytokine family consists of six members, IL-17A-F, with IL-17A the 
most extensively studied member to date. Upon binding of IL-17A to its heterodimeric 
receptors (IL-17RA/RC), various adaptor proteins containing unique interaction domains 
are recruited to the receptor complex, activating multiple pathways, which include 
mitogen activated protein kinases (MAPK) and nuclear factor kappa B (NF-κB). Aberrant 
IL-17 signaling has been functionally linked to the pathogenesis of a variety of 
autoimmune and inflammatory diseases, including multiple sclerosis, systemic lupus 
erythematosus, psoriasis, rheumatoid arthritis and asthma [1-5]. Although T lymphocytes 
are the main source of IL-17A, the expression of IL-17Rs appears to be more ubiquitous 
[6], and the role of structural cells, including epithelial cells, as major responders to IL-
17A has been well documented [7-9]. Airway epithelial cells have been shown to 
upregulate many pro-inflammatory mediators and genes involved in host-defense 
following stimulation with IL-17A. These include beta defensins, mucin genes and 
dendritic cell and neutrophil chemoattractants [7, 10, 11], in part due to the activation of 
the transcription factor NF-κB. 
Previous studies in our laboratory have demonstrated the importance of NF-κB 
activation within lung epithelial cells in the pathogenesis of allergic airways disease in 
mouse models [12-14]. Two parallel NF-κB activation pathways have been described to 
date: the classical and alternative pathways. In the classical pathway, inhibitor of kappa B 
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kinase β (IKKβ) becomes activated via phosphorylation, allowing it to then 
phosphorylate inhibitor of kappa B α (IκBα), marking it for ubiquitination and 
subsequent proteasomal degradation. This event facilitates nuclear entry of the 
transcription factor heterodimer RelA/p50, and subsequent gene induction. In the 
alternative NF-κB pathway, IKKα activation leads to the phosphorylation of p100 and its 
resultant processing to the active p52 form, and allows nuclear entry of the RelB/p52 
heterodimer [15, 16]. The alternative pathway has typically been considered to function 
primarily in cells of the adaptive immune system and lymphoid organs, but more recent 
studies have demonstrated that both NF-κB pathways can cooperate to control pro-
inflammatory responses in lung epithelial cells [17]. 
Given the central role of NF-κB in driving inflammatory responses, its activation 
is tightly regulated via protein-protein interactions as well as several post-translational 
modifications. Reversible oxidative modifications of cysteines, including sulfenic acid 
formation and protein S-glutathionylation (PSSG), have been shown to affect protein 
function [18-20]. PSSG represents the conjugation of the tripeptide antioxidant, 
glutathione (GSH), to reactive, oxidizable cysteines within proteins. This modification 
has considerable implications for biological processes, as it can alter the function of 
various proteins, and both PSSG-induced activation and inactivation have been reported, 
depending on the protein target [21]. Work by our laboratory and others has demonstrated 
that the NF-κB pathway, as well as upstream adaptor molecules such as TRAF6, are 
negatively regulated via PSSG [22-26]. Under physiological conditions, the thiol 
oxidoreductase glutaredoxin-1 (Grx1) can deglutathionylate proteins, thus restoring the 
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native thiol form of the target cysteine residue [27]. Numerous studies initially  focused 
on oxidant-induced PSSG, but more recent studies have demonstrated the role of this 
modification in the context of biologically relevant stimuli [22, 28-30]. 
Although IKKα acts as a positive regulator of IL-17A production in T-cells [31] 
and has also been shown to regulate IL-17A responses in synoviocytes, kidney cells and 
astrocytes [32], the role of epithelial IKKα in response to IL-17A is unclear. To date, it is 
also unknown whether IL-17A elicits redox perturbations in lung epithelial cells, and 
whether redox modifications alter pro-inflammatory responses to IL-17A. Because of the 
known regulation of the NF-κB pathway through PSSG, the ability of Grx1 to reverse 
this modification, and the possible link between IKKα and IL-17A, we focused herein on 
the role of the Grx1/PSSG redox axis in regulating the IKKα-driven responsiveness of 
lung epithelial cells to IL-17A.  
 
Materials and Methods 
Antibodies: The following antibodies were used in this study: rabbit anti-RelA, rabbit 
anti-RelB (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-Histone H3, rabbit 
anti-IκBα (Cell Signaling Technology, Danvers, MA), mouse anti-GSH (Virogen, 
Watertown, MA), mouse anti-IKKα (Upstate, Millipore, Billerica, MA) Streptavidin 
conjugated-HRP (Jackson, West Grove, PA), goat anti-Grx1 (American Diagnostica, 
Stamford, CT) and mouse anti--actin (Sigma-Aldrich, Saint Louis, MO). The secondary 
HRP conjugated anti-rabbit and anti-mouse antibodies were from Amersham 
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(Piscataway, NJ), anti-goat was from Jackson Laboratories (West Grove, PA). All 
fluorophore-conjugated antibodies were from Invitrogen (Carlsbad, CA). 
 
Cell Culture: Primary mouse tracheal epithelial cells (MTECs) were isolated from WT 
mice or mice lacking the glutaredoxin-1 gene (referred herein as Glrx1 -/-), and cultured 
as previously described [33, 34]. A spontaneously transformed type II mouse lung 
alveolar epithelial cell line [35] (C10) was cultured as described previously [33]. Unless 
otherwise noted, 16 h prior to stimulation, C10 cells were switched to medium containing 
0.5% FBS; MTECs were incubated for 16h in serum-free medium. Cells were stimulated 
with indicated concentrations of Interleukin-17A (IL-17A; R&D Systems, Minneapolis, 
MN) and harvested as previously described [36]. 
 
Transfection of siRNA: C10 cells were incubated with scrambled, non-targeting siRNA or 
Grx1 siRNA (Ambion, Carlsbad, CA) (all at 100 nM). C10 cells were incubated with 
SMARTpool scrambled non-targeting siRNA or SMARTpool IKKα siRNA (Dharmacon, 
Lafayette, CO) (all at 100nM). Cells were subsequently stimulated, harvested and 
analyzed as indicated. 
 
Labeling of sulfenic acids using dimedone: Cells were switched to serum-free medium 
for 2 hours; in the final hour, cells were pre-incubated with 1 mM DCP-Bio1 (Kerafast, 
Boston, MA) in serum-free medium for 1h at 37
o
 C. Medium containing DCP-Bio1 was 
removed, and fresh serum-free medium containing 100 ng/ml IL-17A was added to cells 
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for indicated times. Cells were then fixed in 4% formalin and permeabilized with 0.2% 
Triton X100 in PBS for 10 min. The permeabilized cells were blocked in 5% BSA in 
PBS for 1h. The cells were then incubated with fluorescently labeled streptavidin 
(1:2000, SA alexa fluor 647) and the nucleus was counterstained with DAPI (1:4000). 
Cell images were acquired using a Zeiss LSM 510 META Confocal Laser Scanning 
Imaging System. All images were taken at 20X magnification. The image files were 
converted to tiff format and brightness and contrast were adjusted equally in all images. 
 Alternatively, cells were harvested in the presence of dimedone to detect oxidized 
cysteines in cell lysates according to a previously described method [37]. In brief, cells 
were serum-deprived for 2h, and then stimulated with IL-17A and lysed in buffer 
containing 1mM dimedone. Excess dimedone was removed using Micro Bio-spin 6 
columns (Bio-Rad, Hercules, CA). Samples were analyzed by SDS-PAGE, and extent of 
sulfenic acid labeling was assessed using anti-dimedone antibody (Millipore, Darmstadt, 
Germany). 
 
Detection of S-glutathionylated proteins (PSSG): Cells were exposed to IL-17A as 
indicated, and at the selected times lysates were prepared as described before [38]. In 
brief, samples were immunoprecipitated (IP) using GSH antibody (2μg/ml) and 
precipitated proteins were subjected to polyacrylamide gel electrophoresis and 
subsequent immunoblotting for IKKα [38]. As a reagent control, samples were treated 
with 50mM DTT prior to IP, to decompose PSSG. In selected experiments, cells were 
incubated with 250µM biotinylated gluthathione ethyl ester (Bio-GEE) for 1h. Bio-GEE 
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was prepared as previously described [39], and Bio-GEE-conjugated proteins were 
determined following non-reducing SDS-PAGE and Western blotting [39]. Western Blots 
were analyzed via densitometry, and  
Total levels of PSSG in cell lysates were determined using the 
glutathione/glutathione reductase/NADPH/5,5’-dithiobis (2-nitrobenzoic acid) (DTNB) 
recycling assay, according to procedures described previously [40]. Briefly, lung tissue 
was homogenized in buffer containing 137 mM Tris·HCl, pH 8.0, 130 mM NaCl, and 1% 
NP-40. After determination of protein concentration, protein content was equalized and 
500μg of protein was precipitated with acetone. Following centrifugation, the pellet was 
resuspended in buffer containing 0.1% Triton X-100 and 0.6% sulfasalicylic acid and 
freeze-thawed twice. Protein-associated glutathione was released with sodium 
borohydride, and total GSH levels were determined. The sodium borohydride-sensitive 
fraction of GSH released from proteins was calculated and expressed as nanomoles GSH 
per milligram of protein. 
 
mRNA analyses: Total RNA was isolated from cells and purified using the RNeasy kit 
(Qiagen, Valencia, CA) and reverse transcribed to cDNA for taqman gene analysis using 
SYBR green (Bio-Rad, Hercules, CA). Expression values were normalized to the 
housekeeping gene cyclophilin. Primers used were: KC; forward 
GCTGGATTCACCTCAAGAA, reverse TGGGGACACCTTTTAGCATC, IL-6; 
forward CTGATGCTGGTGACAACCAC, reverse CAGAATTGCCATTGCACAAC, 
CCL20; forward AAGACAGATGGCCGATGAAG, reverse 
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AGCCCTTTTCACCCAGTTCT, cyclophilin; forward 
TTCCTCCTTTCACAGAATTATTCCA, reverse CCAGTGCCATTATGG.  
 
Enzyme-Linked Immunosorbent Assays (ELISA): Cells were stimulated, and medium was 
assayed for KC, CCL-20 and IL-6 (R & D Systems, Minneapolis, MN) according to 
manufacturer’s instructions. 
 
Statistical analyses: Statistical analyses were performed using Graphpad Prism software 
(GraphPad, San Diego, CA) using one- or two-way ANOVA with Bonferroni correction 
for multiple comparisons. All experiments were conducted at least three times and data 
are presented as mean values plus the standard error of the mean. 
 
Results 
IL-17A activates classical and alternative NF-κB pathways 
Recent work in our laboratory has provided insights into the interaction of the 
classical and alternative NF-κB pathways in controlling inflammatory responses in 
airway epithelial cells [17]. IL-17A-induced classical NF-κB activation in airway 
epithelial cells has been well documented [7, 10, 41, 42], but only recently was it 
demonstrated that IL-17A can also activate the alternative NF-κB pathway [17]. Results 
in Figure 1A and B demonstrate activation of the classical NF-κB pathway, as indicated 
by phosphorylated forms of RelA and IκBα (Fig. 1A) as well as IκBα degradation and 
increases in nuclear RelA content (Fig. 1B). Expression of IκBα and A20, negative 
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regulators of NF-κB which are induced upon activation of NF-κB, was enhanced 
following IL-17A exposure (Fig. 1C). In response to IL-17A, slight increases in nuclear 
RelB content occurred over time, indicative of alternative NF-κB activation (Fig. 1B).  
These data demonstrate that IL-17A activates both classical and alternative NF-κB in 
lung epithelial cells. 
 
Cysteine oxidation and protein S-glutathionylation are increased following IL-17A 
exposure 
Given that modifications of cysteines play an important role in protein regulation, 
we next investigated whether IL-17A stimulation leads to perturbations in the cellular 
redox environment through determination of cysteine redox modifications. We utilized 
dimedone or a dimedone-based derivative (DCP-Bio1) to measure the extent of sulfenic 
acid formation following stimulation with IL-17A. Cells were either lysed in the presence 
of dimedone to trap sulfenic acid moieties or pre-incubated with DCP-Bio1 and then 
stimulated with IL-17A to visualize oxidation of cysteines via immunofluorescence. 
Results in Figure 2 demonstrate a rapid increase in sulfenic acid formation of numerous 
proteins based upon dimedone labeling and analysis via western blot (Fig. 2A) and 
immunofluorescence analysis (Fig. 2B). In cells stimulated with IL-17A, sulfenic acid 
residues were detectable predominantly in the periphery of the cell, suggestive of 
compartmentalization of sulfhydryl oxidations.   
Because sulfenic acid formation is believed to be a gateway for further cysteine 
modifications, we next asked if S-glutathionylation (PSSG) was also increased in 
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response to stimulation of cells with IL-17A. Glutathione-conjugated proteins from cell 
lysates were assessed by non-reducing SDS-PAGE analysis. Incubation with an anti-GSH 
antibody revealed a time-dependent increase in overall glutathione-adducted proteins in 
response to IL-17A (Fig. 3A). Overall PSSG content measured following release of GSH 
from precipitated proteins also showed trends towards increases in PSSG in epithelial 
cells stimulated with IL-17A at early time points (Fig. 3B). Extensive data exists to 
support a functional role for PSSG of NF-κB components in controlling the activity of 
this pathway [22-25], including work in our laboratory demonstrating the importance of 
IKKβ S-glutathionylation (IKKβ-SSG) [23, 43]. Therefore, we next examined the 
glutathionylation status of specific proteins in the NF-κB pathway after IL-17A 
stimulation. Although we were unable to consistently detect IKKβ-SSG in response to 
IL-17A (data not shown), we did detect increases in RelA-SSG and IKKα-SSG (Fig. 3C), 
which occurred in a biphasic manner. The bi-phasic changes in RelA-SSG and IKKα-
SSG could reflect alterations in expression of Grx1. However, assessment of Grx1 
protein content revealed no differences in expression (Fig. 3C) suggesting that time-
dependent alterations of PSSG in response to IL-17A are not a mere reflection of 
differences in Grx1 content. Overall, these data indicate that IL-17A stimulation leads to 
a rapid increase in sulfenic acid and PSSG in lung epithelial cells, and that RelA and 





Glutaredoxin 1 plays an important role in controlling epithelial cell responsiveness to IL-
17A 
Under physiological conditions, the oxidoreductase Grx1 can catalyze the 
deglutathionylation of proteins, restoring their native structure and function, and IKKβ is 
known to be a substrate for this enzyme [23, 43]. Therefore, we hypothesized that Grx1 
plays a role in IL-17A signaling by deglutathionylating NF-κB proteins, namely RelA 
and IKKα. First, we evaluated the effects of siRNA-mediated ablation of Grx1 on NF-κB 
activation by assessing nuclear content of RelA and RelB in response to IL-17A. RelA 
nuclear content was increased acutely after ablation of Grx1, compared to siRNA control 
cells exposed to IL-17A (Fig. 4A). In contrast, while nuclear content of RelB increased in 
response to IL-17A in siRNA control transfected cells, nuclear content of RelB in cells 
subjected to Grx1 ablation did not appear to change (Fig. 4A), indicating differential 
regulation of both NF-κB pathways by Grx1. The kinetics of nuclear RelA and RelB 
accumulation in response to IL-17A were slightly different as compared to Fig. 1B, likely 
the result of transfection of the cells.  Interestingly, ablation of Grx1 also led to a baseline 
increase in mRNA expression of A20, which was further increased in response to IL-
17A, compared to siRNA controls (Fig. 4B), indicating that certain facets of the NF-κB 
signaling pathway may be intrinsically dampened in the absence of Grx1. 
We next analyzed the impact of siRNA-mediated ablation of Grx1 on the 
expression of pro-inflammatory cytokines induced by IL-17A. IL-17A-induced mRNA 
expression of KC and CCL20 was substantially decreased following ablation of Grx1 
(Fig. 5A), and similar decreases in content of these cytokines were apparent subsequent 
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to Grx1 ablation (Fig. 5B), pointing to a requirement of Grx1 in augmenting the 
production of these cytokines. Intriguingly, the ability of  IL-17A to increase expression 
of IL-6 mRNA and protein was markedly increased in C10s following siRNA mediated 
ablation of Grx1, in contrast to siRNA control transfected cells which demonstrated only 
small increases in IL-6 upon stimulation with IL-17A (Fig. 5A & B). Similar patterns of 
expression of KC, CCL20 and IL-6 were seen in primary mouse tracheal epithelial cells 
(MTECs) lacking the glutaredoxin-1 gene (Glrx1) following stimulation with IL-17A 
(Fig. 5C), further solidifying the importance of Grx1 in controlling epithelial cell 
responses to IL-17A. These data suggest an important functional role for Grx1 in 
controlling IL-17A-induced pro-inflammatory signaling. These findings also illuminate 
the unique impact of Grx1 in regulating pro-inflammatory responses to IL-17A in lung 
epithelial cells, which are highly dependent on the target gene. 
 
S-glutathionylation of RelA and IKKα is controlled by glutaredoxin 1 
In order to further understand the mechanism by which Grx1 controls IL-17A-
induced pro-inflammatory responses, we first evaluated the overall patterns of  PSSG 
following ablation of Grx1. Cells were incubated with a biotinylated form of GSH (Bio-
GEE) 1h prior to stimulation with IL-17A, and harvested at various time points. Results 
in Fig. 6A demonstrate a time-dependent increase in numerous Bio-GEE-conjugated 
proteins in response to IL-17A, some of which are further increased following Grx1 
ablation, even in unstimulated control cells. We next determined whether RelA-SSG and 
IKKα-SSG are potential substrates for Grx1-mediated deglutathionylation, which may act 
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to control IL-17A-induced pro-inflammatory signaling. Immunoprecipitation of S-
glutathionylated proteins revealed a biphasic pattern of both RelA-SSG and IKKα-SSG in 
siRNA control transfected cells stimulated with IL-17A (Fig. 6B). The kinetics of 
increases in RelA-SSG and IKKα-SSG are somewhat different to earlier observations in  
Fig. 3C, likely due to the transfection protocol used. Nonetheless, IL-17A-mediated 
increases in RelA-SSG and IKKα-SSG were more pronounced subsequent to Grx1 
ablation (Fig. 6B). Taken together, these data suggest a direct role for Grx1 in controlling 
the extent of both RelA-SSG and IKKα-SSG. 
 
Loss of IKKα results in dampened IL-17A responses in airway epithelial cells 
The relationship between IKKα and IL-17A has been established in various cell 
types, but the role of epithelial IKKα in controlling IL-17A responses is unknown. 
Therefore, we investigated the functional link between IKKα and IL-17A signaling in 
airway epithelial cells. Ablation of IKKα using siRNA resulted in small reductions in 
nuclear content of both RelA and RelB in response to IL-17A stimulation (Fig. 7A), in 
conjunction with diminished expression of KC and CCL20 (Fig. 7B). Ablation of IKKα 
using siRNA did not alter IL-6 expression in response to IL-17A (data not shown). These 
data collectively indicate a role for both Grx1 and IKKα in controlling airway epithelial 
cell responses to IL-17A stimulation, and that IKKα-SSG correlates with the magnitude 






 The Interleukin-17 (IL-17) family of cytokines has garnered much recent 
attention. For example, a protective role of IL-17A has been demonstrated in host defense 
against bacterial infections [44-47]. Conversely, a pathogenic role of IL-17A has 
emerged in settings of autoimmune diseases, neutrophilic inflammation, cancer, and 
fibrotic tissue remodeling [48-51]. Therefore, an understanding of the molecular 
mechanisms whereby IL-17 family members elicit biological responses is of critical 
importance towards the development of therapeutics aimed at targeting this family of 
cytokines [6, 52, 53]. IL-17A is the most well characterized member, and proximal 
signaling events induced at the IL-17RA/C complex have been well characterized [6]. 
Thiol/redox perturbations are emerging as cardinal regulators of many biological 
pathways, yet it remains unclear whether IL17A elicits any redox changes and whether 
these events affect the cellular responses to IL-17A. In the present study we demonstrate 
that exposure to IL-17A induced rapid protein thiol oxidations, evidenced by increases in 
sulfenic acid formation and S-glutathionylated proteins. We also demonstrated that RelA 
and IKKα are both targets for IL-17A-induced PSSG, and that IKKα contributes to pro-
inflammatory signaling in lung epithelial cells. Furthermore, Glutaredoxin-1 (Grx1) 
controlled both RelA-SSG and IKKα-SSG, and regulated the profile and magnitude of 
pro-inflammatory responses. Overall these findings illuminate a new dimension of IL-
17A-induced biological responses that involve a thiol/redox control mechanism. 
Studies herein have focused on the response of airway epithelial cells to IL-17A. 
The airway epithelium is the first line of defense against inhaled insults and stimuli, and 
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proper functioning of airway epithelial cells is necessary to maintain proper homeostasis 
in the lung [54, 55]. The airway epithelium also plays a vital role in responding to both 
external and internal signals to control the extent of inflammatory responses. Thus, 
airway epithelial cells are a major target of IL-17A, and have previously been shown to 
produce various host defense and pro-inflammatory mediators upon IL-17A exposure [7, 
8, 10, 11]. IKKα plays a role in both classical and alternative NF-κB pathways, but  also 
has NF-κB independent functions [56]. IKKα was originally demonstrated to play a role 
in adaptive immune responses and lymphoid organ development [57]. More recently, a 
functional role for IKKα in regulating polarization of IL-17-producing T helper 17 
lymphocytes has been demonstrated [31] and IKKα has also been shown to regulate the 
responsiveness of synoviocytes, kidney cells and astrocytes to IL-17A [32]. The role of 
IKKα in regulating the responsiveness of epithelial cells to IL-17A had not been 
previously demonstrated. Results from the present study not only show the functional 
importance of IKKα in regulating the responsiveness of epithelial cells to IL-17A, but 
also show that the outcome of IL-17A signaling in epithelium is controlled by the 
Grx1/PSSG axis, in association with IKKα-SSG. These observations have broad 
implications not only for IL-17A-induced pro-inflammatory responses, but also for other 
stimuli that signal through IKKα, as these may also be regulated by Grx1-mediated 
PSSG. However, additional studies are needed to map the reactive cysteine within IKKα 




The functional impact of RelA-SSG had been established previously, as studies 
have shown both inhibition of RelA nuclear entry [22, 58] and DNA binding [59] 
following RelA-SSG. Paradoxically, we demonstrate here that IL-17A-induced RelA-
SSG corresponded to increases in nuclear RelA, which were further enhanced following 
ablation of Grx1. These results indicate that, in response to IL-17A, nuclear translocation 
of RelA may not be affected by its S-glutathionylation, but that RelA-SSG could interfere 
with DNA binding, as has been shown previously following oxidant-triggered PSSG in 
vitro [59]. Further investigation is needed to determine the functional role of RelA-SSG 
in response to IL-17A, which was beyond the scope of the current study. 
It is plausible that other components of the IL-17 pathway, in addition to RelA 
and IKKα, may be targets for thiol/redox control. In this regard, TRAF6 was recently 
described as a target for Grx1-mediated deglutathionylation in the context of TLR/IL1R 
signaling [26]. Since the IL-17R complex also utilizes this adaptor molecule for the 
activation of NF-κB [6], it is plausible that TRAF6 is also a target for PSSG in cells 
stimulated with IL-17A. A recent study demonstrated the importance of A20 in negative 
feedback regulation of IL-17A-induced cellular responses [60]. A20 is one of several de-
ubiquitinases that has been shown to be a target for reversible oxidations which regulate 
its activity [61]. The active site cysteine of A20 in particular was demonstrated as a target 
of hydrogen peroxide-induced oxidation, resulting in inhibition of its deubiquitinase 
activity [61]. It is plausible that PSSG also inhibits de-ubiquitinase activity of A20, 
thereby regulating the responsiveness of epithelial cells to IL-17A, scenarios that will 
require further investigation. It is worthy to mention that Grx1 status regulates mRNA 
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expression of A20, and that absence of Grx1 led to a two fold increase of A20 mRNA. 
Despite this apparent link between A20 and Grx1, the specific mechanisms whereby 
Grx1 regulates A20 remain to be further elucidated.  
The opposing outcome of IL-17A-induced KC and CCL20 expression compared 
to IL-6 expression following ablation of Grx1 is intriguing. While ablation of Grx1 
attenuated IL-17A-induced expression of KC and CCL20, ablation of Grx1 augmented 
the ability of IL-17A to induce IL-6, and similar effects were observed in two distinct 
epithelial cell cultures. These results clearly demonstrate that ablation of Grx1 does not 
dampen the overall pro-inflammatory response, but rather that ablation of Grx1 modifies 
the nature of the pro- inflammatory response of epithelial cells to IL-17A. It remains 
unclear whether the altered cellular responses to IL-17A following ablation of Grx1 are 
indeed due to altered function of NF-κB, and whether this involves RelA/p50 or 
RelB/p52 heterodimers, the latter of which are known to bind to a broader spectrum of 
kappaB sites [62]. Following ablation of Grx1, the overall nuclear content of RelA was 
acutely increased, whereas nuclear RelB content tended to decrease in response to IL-
17A, as compared to respective siRNA controls. Thus, an altered balance of RelA/p50 or 
RelB/p52 dimers could account for the observed changes of pro-inflammatory responses 
to IL-17A. In this regard, prior studies have indicated that active RelB dimers can repress 
transcription of IL1B and IL12B genes [63], and that in association with decreased RelB, 
IL-6 levels increased [64]. C-Rel is important in the transcriptional regulation of IL6 [65], 
which raises the possibility that Grx1 may alter IL6 gene expression via c-Rel. 
Alternatively, it is possible that other transcription factors modulate pro-inflammatory 
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gene expression following modulation of Grx1 which could account for the differential 
responses of IL-6 expression as compared to KC and CCL20. Future studies mapping 
transcription factor occupancy at the promoters of these cytokine genes will be required 
to fully understand these scenarios.  
Results from the present study demonstrate increases in sulfenic acid formation 
and PSSG in response to IL-17A. Numerous studies have previously demonstrated these 
oxidative events under conditions of overt stress, or in response to direct exposure to an 
oxidant. The subtle patterns of oxidations demonstrated herein are reflective of a 
biological stimulus that elicits a cellular response without creating overt cellular stress, 
nor inducing cell death. The source of oxidants following IL-17A stimulation remains 
unknown. Increased sulfenic acid formation was observed as early as five minutes 
following IL-17A stimulation, and appeared to be localized primarily near the cell 
periphery (Fig. 2B). In the context of TLR/IL-1R signaling, previous studies have 
observed an oxidant-dependent recruitment of TRAF6 to the receptor complex, via non-
phagocytic NADPH oxidase 2 (Nox2), which is necessary for signal propagation [66]. 
The pattern of sulfenic acid formation observed herein could potentially reflect a similar 
NADPH oxidase-induced signaling event that is localized to the IL-17R complex. 
Activation of Nox2 following engagement of the IL17R may potentially be responsible 
for the production of oxidants, which in turn lead to sulfenic-acid containing proteins. 
Indeed, further analyses will be required to fully determine the source of oxidants and the 
specific subcellular localization of these oxidative events. 
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The biochemical links between sulfenic acid intermediates and PSSG in 
biological settings remain poorly understood. Sulfenic acid intermediates can be unstable 
and give rise to further oxidations [67]. PSSG of sulfenic acid intermediates is believed to 
be important in the protection of cysteines against overoxidation [68]; therefore, it is 
plausible that sulfenic acid intermediates observed in response to IL-17A are the 
precursor to PSSG. The mechanisms that govern PSSG in response to IL-17A also 
remain unknown. PSSG can occur spontaneously, notably under conditions of oxidative 
stress when an abundance of oxidized glutathione (GSSG) is present [19]. Enzymatic 
catalysis of PSSG by glutathione S-transferase Pi (GSTP) has been demonstrated under 
conditions of oxidative stress [69], or in response to the death inducing ligand FasL [70]. 
It remains unknown at this time whether GSTP, a protein that is highly expressed in lung 
epithelial cells [71], plays a role in the catalysis of IKKα-SSG in response to IL-17A.  
 In summary, results from the present study demonstrate that the pro-inflammatory 
response elicited by IL-17A is controlled by the S-glutathionylation/Grx1 redox axis in 
association with RelA-SSG and IKKα-SSG. Therefore, avenues that target the protein 
thiol redox status can be exploited to harness the cellular response to IL-17A and have 









Figure 1: Activation of classical and alternative NF-κB pathways in lung epithelial cells 
in response to IL-17A. (A) Mouse alveolar type II cells (C10) were stimulated with IL-
17A (100ng/ml) and NF-κB was assessed in whole cell lysates by measuring 
phosphorylated forms of RelA (pRelA) and IκBα (pIκBα). β-actin; loading control. Right 
panels: densitometric evaluation of pRelA and pIκBα. Data reflect arbitrary units, 
following normalization to loading control, β-actin.  (B) Assessment of nuclear RelA and 
RelB content and degradation of cytosolic IκBα following stimulation with IL-17A 
(50ng/ml) in C10 cells. β-actin; loading control for cytosolic lysates, (labeled as C); 
Histone H3 (H3) was used as a loading control for nuclear lysates, (labeled as N). Right 
and bottom panels: densitometric evaluation of  nuclear RelA,  nuclear RelB and IκBα. 
Data reflect arbitrary units, following normalization to respective loading controls.   (C) 
Evaluation of mRNA expression of NF-κB-dependent negative regulators A20 and IκBα 
via real-time PCR in C10 cells stimulated with IL-17A (50ng/ml). Results were 
normalized to the housekeeping gene cyclophilin and are presented as relative expression. 
*p≤0.05 (ANOVA), compared to untreated controls (Sh). 
 
Figure 2: IL-17A increases cysteine oxidation in lung epithelial cells. (A) C10 cells were 
stimulated with IL-17A (50ng/ml) for indicated times and subsequently harvested in the 
presence of dimedone (1mM) to trap the sulfenic acid form (SOH) of cysteines. Samples 
were analyzed via reducing SDS-PAGE, and overall sulfenic acid formation was 
determined using an anti-dimedone antibody (1:1000). -Dim, minus dimedone control. 
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(B) Assessment of SOH formation (red) via immunofluorescence in C10 cells pre-
incubated with DCP-Bio1 (1mM) for 1h and stimulated with 100ng/ml IL-17A for 
indicated times. An anti-biotin Alexafluor-647 secondary antibody was used to visualize 
DCP-Bio1- bound proteins. Nuclei are counterstained with DAPI (blue). No DCP-Bio1; 
omission of DCP-Bio1 label. 
 
Figure 3: Increases in protein S-glutathionylation in C10 cells stimulated with IL-17A. 
(A) C10 cells were stimulated with 50ng/ml IL-17A, and whole cell lysates were 
harvested at indicated times. SDS-PAGE analysis was performed under non-reducing 
conditions and GSH-conjugated proteins were assessed using an anti-GSH antibody 
(1:1000). A separate sample was incubated with (+DTT) to decompose S-
glutathionylated proteins. (B) Following stimulation with 50ng/ml IL-17A, C10 cells 
were harvested at indicated times and overall S-glutathionylation was evaluated using the 
DTNB recycling assay. (C) C10 cells were stimulated with 50ng/ml IL-17A and 
harvested as indicated. S-glutathionylated proteins (200μg protein/sample) were 
immunoprecipitated (IP) using an anti-GSH antibody (2μg/ml) overnight at 4o C. 
Following IP, samples were subjected to SDS-PAGE and Western Blot analysis using 
RelA and IKKα antibodies. WCL: Whole cell lysates to confirm equal content of RelA 
and IKKα, or Grx1. +DTT, control sample incubated with DTT to decompose S-
glutathionylated proteins.  β-actin: loading control. 
Bottom panel: densitometric evaluation of IKKα-SSG and RelA-SSG. Data reflect 




Figure 4: Ablation of Grx1 alters NF-κB activation and mRNA expression of A20. (A) 
Assessment of NF-κB activation following siRNA-mediated ablation of Grx1 or control 
siRNA and stimulation with IL-17A (50ng/ml). Nuclear (N) and cytosolic (C) lysates 
were harvested from C10 cells and nuclear content of RelA and RelB (top panels) was 
assessed. Histone H3 (H3); loading control.  Bottom panels:  Evaluation of Grx1 in 
cytosolic lysates to confirm siRNA-mediated ablation. β-actin; loading control. Graphs 
represent densitometric evaluation of nuclear RelA and RelB. Data reflect arbitrary units, 
following normalization to the loading Histone H3.  (B) C10 cells were subjected to 
siRNA-mediated ablation of Grx1 or control siRNA, and stimulated with IL-17A for 
indicated times, and A20 mRNA expression was evaluated. Results were normalized to 
the housekeeping gene cyclophilin and are presented as relative expression.  
 
Figure 5: Grx1 SiRNA or genetic ablation of Glrx1 alters pro-inflammatory responses in 
lung epithelial cells. C10 cells stimulated with IL-17A (50ng/ml) for indicated times 
were analyzed for mRNA expression (A) and protein levels (B) of KC, CCL20 and IL-6 
following siRNA-mediated ablation of Grx1 or control siRNA. (C) Expression of KC, 
CCL20 and IL-6 in WT or Glrx1-/- primary mouse tracheal epithelial cells (MTECs) 
following stimulation with IL-17A (20ng/ml). Expression values were normalized to the 
housekeeping gene cyclophilin, and data are presented as relative expression. * p≤0.05 
(ANOVA) compared to untreated controls (Sh); † p≤0.05 (ANOVA) compared to scr 




Figure 6: Grx1 ablation promotes S-glutathionylation of RelA and IKKα. C10 cells were 
subjected to siRNA-mediated ablation of Grx1 or control siRNA. (A) Cells were pre-
incubated with Bio-GEE (250μM) for 1h prior to stimulation with IL-17A (50ng/ml), and 
subsequently harvested at indicated times. SDS-PAGE performed under non-reducing 
conditions, followed by Western Blot analysis of Bio-GEE-conjugated proteins assessed 
via streptavidin-HRP. –BG; control wherein the Bio-GEE label was omitted. ns; non-
specific bands. (B and C) Following siRNA-mediated ablation of Grx1, C10 cells were 
stimulated with IL-17A (50ng/ml) and harvested at indicated times. S-glutathionylated 
proteins were immunoprecipitated with GSH antibody (2μg/ml) and resolved via SDS-
PAGE and western blotting for IKKα (B) or RelA (C). Bottom panel: western blot 
showing confirmation of Grx1 ablation. Right panels: densitometric evaluation of IKKα-
SSG and RelA-SSG. Data reflect arbitrary units, following normalization to total IKKα 
or RelA.   
 
Figure 7: SiRNA-mediated ablation of IKKα modulates expression of pro-inflammatory 
mediators in lung epithelial cells. (A) Assessment of nuclear RelA and RelB following 
siRNA-mediated ablation of IKKα or control siRNA and stimulation with IL-17A 
(50ng/ml). Nuclear (N) and cytosolic (C) lysates were harvested from C10 cells and 
nuclear content of RelA and RelB was assessed. Histone H3 (H3) was used as a loading 
control. Bottom panels: Assessment of IKKα in cytosolic lysates to confirm siRNA-
mediated ablation. β-actin; loading control. Graphs represent densitometric evaluation of 
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nuclear RelA and RelB. Data reflect arbitrary units, following normalization to the 
loading Histone H3.   (B) Assessment of KC and CCL20 mRNA expression following 
siRNA-mediated ablation of IKKα and stimulation with IL-17A (50ng/ml) at indicated 
times. Values were normalized to the housekeeping gene cyclophilin, and data presented 
and relative expression. * p≤0.05 (ANOVA) compared to untreated controls (Sh); † 
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THE THIOL TRANSFERASE GLUTAREDOXIN-1 ATTENUATES HOUSE DUST MITE-INDUCED 
FIBROTIC AIRWAY REMODELING 
Abstract 
Allergic airways disease is accompanied by changes in the redox environment, 
although the exact functional role of redox changes in disease pathogenesis remains 
unknown.  Protein S-glutathionylation (PSSG) represents an oxidative modification of 
reactive protein cysteines and has emerged as a key regulatory event in biological 
processes. Under physiological conditions, the thiol transferase, glutaredoxin-1 (Glrx1), 
can deglutathionylate protein cysteines, restoring the reduced protein thiol group. In the 
present study we addressed the functional role of Glrx1 in house dust mite 
(HDM)-induced allergic airways disease using mice that globally lack the Glrx1 gene 
(Glrx1
-/-
) or Bitransgenic mice that inducibly overexpress Glrx1 in airway epithelial cells 
(Epi-Glrx1) upon administration of Doxycycline (Dox). Glrx1
-/- 
mice exposed to HDM 
had increased airway hyperresponsiveness (AHR), increased α-SMA reactivity and 
increased sub-epithelial collagen deposition, compared to respective WT mice. 
Conversely, Epi-Glrx1 mice exposed to HDM displayed decreased AHR and substantial 
protection against sub-epithelial collagen deposition, compared to respective controls. E-
cadherin expression, a marker of epithelial barrier function, was decreased in Glrx1
-/- 
mice and in primary tracheal epithelial cells obtained from Glrx1
-/- 
mice. Lastly, genetic 
ablation or knockdown of Glrx1 augmented TGFβ1- or HDM-induced decreases in E-
cadherin and increases in α-SMA. Together, these findings demonstrate a cardinal role 
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for Glrx1 in protecting against HDM-induced fibrotic airways remodeling, in association 
























Asthma is a multifaceted disease characterized by chronic inflammation, airway 
hyperreactivity and airway remodeling. Multiple cell types have been implicated in the 
pathogenesis of asthma, and a role of epithelial cells has been clearly established. 
Epithelial cells directly respond to components in allergens, leading to the release of 
mediators, such as IL1α, IL33, and TSLP that in turn control adaptive immune responses 
[1, 2]. Mouse models of allergic airways disease, such as house dust mite (HDM) or 
ovalbumin (Ova), have yielded important insights into the roles that airway epithelial 
cells play in the etiology of allergic airways disease.  
Changes in the redox environment have been demonstrated in a variety of 
pulmonary diseases, including asthma. Increased oxidant production [3, 4], oxidation of 
glutathione [5, 6] and inactivation of antioxidants [7] have been observed in airways of 
asthmatics. It is now becoming widely accepted that oxidants and subsequent 
modifications of various targets may be central players in (patho-) physiological 
processes. Redox homeostasis in the lung is controlled by an extensive network of 
enzymes and small molecules that act in concert to tightly regulate the oxidation of 
proteins and other macromolecules. Oxidation of cysteine thiol groups within proteins 
serves as a sensor that converts an oxidant signal into a biological response. Low pKa 
cysteines are targets for oxidation and can form sulfenic acid, S-nitrosylated, and 
S-glutathionylated intermediates, among others. S-glutathionylation is the conjugation of 
glutathione to protein cysteines and may play a critical role in regulating biological 
processes, as the addition of glutathione alters the charge and conformation of the target 
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protein and subsequently can alter protein function. The process of S-glutathionylation is 
regulated by glutaredoxins, a family of thiol transferases that primarily acts to 
de-glutathionylate proteins under physiological conditions, restoring native cysteine 
sulfhydryl groups [8, 9]. Of particular interest are findings demonstrating that 
S-glutathionylation of proteins within the NF-κB pathway, notably IKΚβ, IKKα, RelA, 
and p50 inhibit NF-κB function and dampen downstream NF-κB dependent signaling 
[10, 11].  
Using the Ova model of allergic airways disease, our laboratory has previously 
demonstrated that global ablation of glutaredoxin-1 (Glrx1
-/-
) leads to attenuated airway 
hyperreactivity in mice of the Balb/C background [12]. Furthermore, elevated Glrx1 as 
well as decreased protein S-glutathionylation has been observed in the airways of patients 
with asthma [13]. In settings of HDM-induced allergic airway disease, the potential role 
of Glrx1 has not been addressed. We therefore sought to examine whether Glrx1 status 
controls inflammation, airway hyperresponsiveness and airways remodeling induced by 
HDM. We utilized mice that globally lack the Glrx1 gene, and mice that inducibly 
overexpress Glrx1 in airway epithelial cells.  
 
Materials and Methods 
Mice: For all experiments, 8-12 week old C57B/6NJ mice were used (The Jackson 
Laboratory, Bar Harbor, ME). Lung epithelial specific overexpression of Glrx1 was 
achieved by crossing mice expressing the Club cell secretory protein (CC10) promoter 5’ 
to the open reading frame of the reverse tetracycline transactivator (CC10-rtTA) with 
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mice expressing the TetOP-FLAG Glrx1 construct [14]. Transgenic mice expressing 
CCSP-rtTA/TetOP-FLAG Glrx1 were fed doxycycline (Dox) containing food (6g/kg, 
Purina Diet Tech, St. Louis, MO) starting 7 days before the first administration of HDM 
and were maintained on Dox food until the completion of the experiment. Bi-transgenic 
mice not fed Dox food, or single transgenic mice expressing only the CCSP-rtTA 
construct were fed Dox food and used as controls. Glrx1
-/-
 mice were described 
previously, and WT littermates served as controls [15]. All studies were approved by the 
Institutional Animal Care and Use Committee at the University of Vermont. Experiments 
were performed at least twice, and animal numbers in each group are noted in each 
figure. 
 
HDM-induced allergic airways disease and assessment of airway hyperresponsiveness: 
WT, Glrx1
-/-
 and Glrx1 TG mice were intra-nasally instilled with HDM extract 
containing 1μg protein (GREER, Lenoir, NC) on days 1 and 8, and on days 15-19 mice 
were instilled with 10ug HDM each day and euthanized 24h after the last HDM 
administration (Fig. 1A). HDM extract contained 35 endotoxin units/mg normalized to 
protein content. Control mice were administered PBS as a vehicle control in each 
experiment. Following completion of the HDM protocol, mice were anesthetized with 
intraperitoneal pentobarbital sodium (90 mg/kg), tracheotomized, and mechanically 
ventilated at 200 breaths/min. Mice were subjected to increasing doses of methacholine 
(0, 12.5 mg, 25 mg and 50 mg) and respiratory mechanics were assessed using a forced 
oscillation technique on a computer-controlled small animal ventilator (SCIREQ, QC, 
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Canada), as previously described [16, 17]. Parameters of Newtonian resistance (Rn), 
tissue resistance (G) and elastance (H) were calculated and quantified by averaging the 
three highest measurements obtained at each incremental methacholine dose for each 
mouse. 
 
Bronchoalveolar lavage: After mice were euthanized, bronchoalveolar lavage (BAL) was 
performed using 1 ml PBS. BAL was collected and total cell counts were determined 
using an Advia 120 Automated Hematology Analyzer. BAL was spun down at 1200xg 
for 5 min. Cells were transferred to slides using a cytospin, fixed in methanol and stained 
using the Hema3 kit (Fisher Scientific, Kalamazoo, MI) and analyzed by counting a 
minimum of 300 cells per mouse, as described elsewhere [16]. Supernatants were flash 
frozen in liquid nitrogen and stored at -80
o
 C until analysis via ELISA.  
 
Measurement of airways fibrosis: The right lung was fixed in 4% PFA and embedded in 
paraffin. Lung sections (5μm) were stained using Masson’s Trichrome to visualize 
collagen. Staining intensity in peribronchiolar regions was analyzed by two independent 
investigators using a scale of 0-3, where 0 indicates no collagen positivity and 3 indicates 
highest levels of collagen staining. Values for each group are presented as averaged 
scores from both investigators. Images were acquired using an Olympus BX50 Light 
Microscope with QImaging Retiga 2000R digital camera. Collagen content was 
determined by isolating the superior lobe of the right lung and measuring the total content 




Cell culture and siRNA transfections: Primary mouse tracheal epithelial cells, isolated as 
described previously [19, 20] and the C10 type II alveolar epithelial cell line [21] were 
exposed to TGFβ (R&D Systems, Minneapolis, MN) or HDM (GREER) where indicated. 
Cells were harvested for western blot analysis or qPCR as noted. For siRNA experiments, 
a spontaneously transformed type II mouse lung alveolar epithelial cell line [21] (C10) 
was incubated with non-targeting siRNA (Scr siRNA) or siRNA targeting Glrx1 
(Ambion, Carlsbad, CA) using Dharmafect reagent (Thermo Scientific, Waltham, MA) 
according to manufacturer’s instructions. All siRNA was used at 100nM final 
concentration. 
 
Assessment of mucus metaplasia: Periodic acid-Schiff staining was performed and the 
extent of mucus metaplasia was evaluated by two independent investigators. Lung 
sections were blinded and ranked on a scale from 0 to 3: 0, no reactivity; 1, minimal 
staining; 2, moderate staining; 3, prominent staining. Data represented are averages of the 
cumulative score from each mouse according to treatment group. 
 
mRNA analyses: RNA was isolated from lung tissue using the RNeasy Kit (Qiagen, 
Valencia, CA) and reverse transcribed for analysis using SYBR green (Bio-Rad, 
Hercules, CA). Primers used were: TGFβ, FW: TGCTTCAGCTCCACAGAGAA, RV: 
TGGTTGTAGAGGGCAAGGAC; αSMA, FW: CGCTGTCAGGAACCCTGAGA, RV: 
CGAAGCCGGCCTTACAGA; Muc5AC, FW: GCTACACCCAGGTTGAGAAGTG, 
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RV: TCCTCACTTTCCTTGGACTTGA. Expression was normalized to β-actin, FW: 
CTGAATGGCCCAGGTCTGA, RV: CCCTCCCAGGGAGACCAA. 
 
Statistical Analyses: Data for differential cell counts, Muc5AC expression and 
hydroxyproline were analyzed by ANOVA. All experiments were repeated at least twice 
and data from combined experiments are represented as mean +/- S.E.M. Scoring of 
histological staining was analyzed by Kruskal-Wallis test and Dunn’s post hoc test. Data 
for AHR were analyzed via least squares mean test. For all analyses, P values ≤0.05 were 





 mice display elevated subepithelial collagen deposition in response to house dust 
mite (HDM) exposure. 
The function of glutaredoxin 1 (Glrx1) has not been thoroughly investigated in settings of 
allergic airways disease, particularly in response to HDM. We have previously shown 
that the antigen ovalbumin (Ova) results in increased Glrx1 in the airways of mice and 
that Glrx1
-/-
 mice have altered resolution of Ova-induced inflammation and airway 
hyperresponsiveness (AHR) [12, 22]. However, a direct role for Glrx1 in the 
pathogenesis of HDM-induced disease has yet to be determined. To address this, we first 
utilized mice globally lacking Glrx1 (Glrx1
-/-
) on the C57BL/6 background to determine 
the impact on HDM-induced AHR, cellular influx and fibrotic remodeling. In mice 
subjected to HDM (Fig. 1A), assessment of cellular influx into the airways in 
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bronchoalveolar lavage (BAL) fluid revealed comparable significant increases in total 
cell counts in WT and Glrx1
-/- 
mice (Fig. 1B). Statistically significant increases in 
neutrophils, eosinophils and lymphocytes were observed in WT HDM-exposed mice 
compared to PBS controls (Fig. 1C). In contrast, in Glrx1
-/-
 mice, statistically significant 
increases in BAL eosinophils and lymphocytes, but not neutrophils, were observed 
following HDM exposure (Fig. 1C). No significant differences were observed in 
macrophages in any of the groups (Fig. 1C) and no significant differences were observed 
between HDM-exposed WT mice and HDM-exposed Glrx1-/- mice. Western blot 
analysis demonstrated increases in Glrx1 protein in lung tissue in WT mice in response to 
HDM, consistent with prior observations following Ova [22] and HDM [23], whereas, as 
expected, no detectable Glrx1 immunoreactivity was observed in Glrx1
-/-
 mice (Fig. 1D). 
 Next we investigated the impact of Glrx1 ablation on HDM-induced airway 
remodeling. Manifestations of airway remodeling include mucus metaplasia, increased 
alpha smooth muscle actin content (αSMA), and elevated subepithelial collagen 
deposition. Mucus metaplasia was significantly increased following exposure to HDM in 
WT and Glrx1
-/-
 mice compared to respective PBS controls(Fig. 2A and B), in association 
with increased expression of the mucin gene, Muc5AC (Fig. 2C). Analysis of αSMA 
immunoreactivity revealed significant HDM-induced increases in both WT mice and 
Glrx1
-/-
 mice (Fig. 2A & B). PAS reactivity and αSMA reactivity tended to be enhanced 
in Glrx1
-/-
 mice as compared to WT animals, although these trends did not reach 
statistical significance. Despite elevated αSMA observed via immunohistochemical 
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analysis, expression of αSMA mRNA was not significantly increased in response to 
HDM in WT or Glrx1
-/-
 mice (data not shown).  
In order to assess the extent of subepithelial fibrosis following HDM exposure, 
immunohistochemical analysis of collagen deposition was investigated. Subepithelial 
collagen was increased in the lungs of HDM-exposed WT mice and was further elevated 
in Glrx1
-/-
 mice (Fig. 2A & B). Hydroxyproline content, indicative of total lung collagen, 
was significantly increased in WT mice exposed to HDM (Fig. 2D). HDM-induced 
increases in hydroxyproline were significantly elevated in Glrx1
-/-
 mice compared to WT 
mice (Fig. 2D). Lastly, we evaluated HDM-induced AHR. In response to HDM, both WT 
mice and Glrx1
-/-
 mice showed significant increases in tissue resistance (G) compared to 
respective PBS groups, whereas airway resistance (Rn) was only significantly increased 
over PBS in Glrx1
-/-
 mice (Fig. 2E). HDM-exposed Glrx1
-/-
mice displayed significantly 
higher AHR in parameters Rn and G compared to WT mice exposed to HDM (Fig. 2E), 
but no significant differences were observed in elastance (H) (Fig. 2E). Together, these 
data suggest that Glrx1
-/-
 mice exhibit enhanced airway remodeling and slight increases 
in AHR compared to WT mice. 
 
Decreases in HDM-induced peri-bronchiolar collagen deposition in transgenic mice 
expressing Glrx1 in airway epithelial cells 
As a complimentary approach, we used a tissue specific, inducible system (CC10-
rtTA/TetOP-FLAG Glrx1) in which mice express Glrx1 specifically in CC10-positive 
airway epithelial cells in the presence of doxycycline (Dox; hereafter referred to as Epi-
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Glrx1 mice). The transgene was activated 7 days prior to the start of experiments and 
HDM was administered as described in Fig. 3A. As controls, mice harboring the CC10-
rtTA transgene but lacking the TetOP-FLAG Glrx1 transgene (hereafter referred to as 
rtTA mice) were given Dox, or CC10-rtTA/TetOP-FLAG Glrx1 mice not receiving Dox 
(hereafter referred to as Bitransgenic mice) were used. HDM exposure resulted in 
significantly elevated total cells in Bitransgenic mice not given Dox and Epi-Glrx1 mice 
compared to respective PBS groups (Fig. 3B). HDM-exposed Epi-Glrx1 mice exhibited 
significantly lower total cells compared to HDM-exposed rtTA mice receiving Dox (Fig 
3B). Furthermore, Epi-Glrx1 mice also displayed a significant decrease in eosinophils 
compared to rtTA mice receiving Dox (Fig. 3C), likely accounting for the observed 
decreases in totals cell counts. Airway neutrophils, eosinophils and lymphocytes were all 
significantly elevated in Bitransgenic mice and Epi-Glrx1 mice compared to respective 
PBS controls, but no significant differences were observed between HDM-exposed 
Bitransgenic mice and HDM-exposed Epi-Glrx1 mice (Fig. 3C). No significant 
differences were observed in macrophages in any group (Fig. 3B). Western blotting of 
lung lysates confirmed Dox-induced transgene activation in Epi-Glrx1 mice (Fig. 3D). 
 Next, we investigated the extent of remodeling in the lungs of Epi-Glrx1 mice. 
Analysis of mucus metaplasia and αSMA immunoreactivity showed increased HDM-
induced mucus in all groups of animals, but no clear impact following expression of the 
Epi-Glrx1 transgene (Fig. 4A). A statistically significant HDM-induced increase in 
Muc5AC mRNA was apparent in both Bitransgenic mice and Epi-Glrx1 mice compared 
to PBS controls (Fig. 4B). In contrast, HDM-mediated increases in hydroxyproline 
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content were significantly attenuated in Epi-Glrx1 mice compared to both Bitransgenic 
mice and rtTA control mice (Fig. 4C), consistent with attenuation of peri-bronchiolar 
Masson’s trichrome reactivity in Epi-Glrx1 mice (Fig 4A). Analysis of AHR revealed 
significant HDM-induced increases in Rn, G and H in Bitransgenic mice not given Dox 
and Epi-Glrx1 mice compared to respective PBS groups (Fig. 4D). A significant decrease 
in elastance (H) was observed in HDM-exposed Epi-Glrx1 mice compared to both 
Bitransgenic mice not given Dox and rtTA mice given Dox, indicating overexpression of 
Glrx1 may protect against certain aspects of AHR (Fig. 4D). Similarly, Epi-Glrx1 mice 
exhibited significantly lower tissue resistance (G) compared to rtTA mice given Dox 
(Fig. 4D). Furthermore, a significant attenuation in airway resistance (Rn) was observed 
in rtTA mice receiving Dox compared to Epi-Glrx1 mice, indicating a potential 
confounding effect of Dox administration itself (Fig. 4D). Overall, the current data 
suggest that overexpression of Glrx1 in airway epithelial cells protects against fibrotic 
airway remodeling and development of AHR. 
 
Absence of Glrx1 promotes mesenchymal transition of epithelial cells 
Due to the importance of Glrx1 in controlling fibrotic airway remodeling in vivo, we next 
analyzed expression of the epithelial marker, E-cadherin, in the lungs of mice. Loss of 
E-cadherin is generally associated with cancer metastasis and epithelial-to-mesenchymal 
transition (EMT), indicating loss of cell-cell contacts [24]. Greater E-cadherin depletion 
has also been reported in airway epithelial cell cultures from asthmatics exposed to 
TGFβ, compared to healthy control cells stimulated with TGFβ, pointing to a 
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compromised ability of the asthmatic epithelium to self-repair [25]. In response to HDM, 
WT mice showed decreased E-cadherin mRNA expression and protein content in lung 
tissue compared to control animals (Fig. 5A and B). Interestingly, Glrx1
-/-
 mice already 
exhibited a decrease in basal expression of E-cadherin that was not significantly altered 
following exposure to HDM (Fig. 5A and B). These data indicate that Glrx1
-/-
 mice may 
have impaired epithelial barrier function prior to allergen exposure. Because we observed 
decreased E-cadherin in Glrx1
-/-
 mice, we next sought to determine the impact of Glrx1 
status on epithelial cell responses to HDM. Similar to the data observed in mice, 
E-cadherin was decreased in WT epithelial cells exposed to HDM for 7 days, but was 
already lower in control Glrx1
-/-
 epithelial cells, and exposure to HDM did not result in a 
further loss of E-cadherin (Fig. 5C).  
A prominent feature of remodeling and fibrotic diseases is enhanced TGFβ 
production and signaling, potentially leading to elevated expression of αSMA and 
collagen. Therefore, we sought to further investigate the importance of Glrx1 in 
mediating aspects of remodeling by stimulating cells with TGFβ and assessing αSMA 
production. In WT cells, no detectable baseline αSMA reactivity was apparent. Upon 
stimulation of cells with TGFβ for 72h, αSMA increased substantially (Fig. 5D, left). 
Interestingly, marked increases in αSMA were observed in unstimulated Glrx1-/- cells and 
were further enhanced following TGFβ stimulation (Fig. 5D, right). Comparable results 
were observed utilizing siRNA targeted against Glrx1. TGFβ-dependent increases in 
αSMA were observed in C10 cells transfected with non-targeting scrambled (Scr) siRNA 
(Fig. 5E, left), but following siRNA-mediated ablation of Glrx1, baseline αSMA was 
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already detectable and further elevated in response to TGFβ exposure (Fig. 5E, right). 
These data indicate a central role for Glrx1 in controlling the extent of fibrotic airways 
remodeling induced by HDM, in association with controlling epithelial barrier function 
and EMT.  
 
Discussion: 
In the current study, we investigated the impact of an altered redox environment 
in a house dust mite (HDM) model of allergic airways disease by utilizing mice globally 
lacking glutaredoxin-1 (Glrx1
-/-
) and mice overexpressing Glrx1 specifically in the 
airway epithelium (Epi-Glrx1). Glrx1 is an oxidoreductase that is primarily responsible 
for deglutathionylation of proteins. An imbalanced redox environment in the lung is 
known to contribute to asthma, with increased lung and blood GSH levels having 
previously been reported [26]. Evidence suggests a role for Glrx1 in mouse models of 
allergic airways disease [12, 22], as well as in patients with asthma, wherein increases in 
airway Glrx1 have been demonstrated in the airways of asthmatics, and lower Glrx1 
correlated with better lung function in these patients [13]. Findings from the present study 
suggest that absence of Glrx1 results in enhanced fibrotic airway remodeling in allergen-
exposed mice. Furthermore, overexpression of Glrx1 can attenuate fibrotic airway 
remodeling, indicating a potential novel role of Glrx1 not yet described in the setting of 
allergic airways disease.  
Previous data from our group indicated that Glrx1
-/-
 mice in the Balb/C 
background exposed to the antigen ovalbumin (Ova) displayed enhanced resolution of 
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airway hyperresponsiveness (AHR) and attenuated mucus metaplasia, demonstrating that 
absence of Glrx1 may be beneficial in controlling certain aspects of the disease [12]. In 
the current study utilizing the relevant allergen HDM, we observed significantly higher  
AHR (parameters Rn and G) in Glrx1
-/-
 mice and significant protection against the 
development of AHR in mice overexpressing Glrx1 in airway epithelial cells (Epi-Glrx1) 
(Fig. 2E and 4E), in comparison to the respective control groups. The apparent 
discrepancy with the previous study may be linked to the strain of mice used, as 
experimental animals used in this study were in the C57Bl/6 background, compared to 
mice in a Balb/C background used in the previous study. Furthermore, the model of 
allergic airways disease used herein, and the timing of analysis relative to the last 
challenge with antigen was also different and could have accounted for apparent 
differences with respect to the impact of Glrx1 on AHR.  
Analysis of cell differentials indicated that Glrx1 may be involved in controlling 
influx of eosinophils and to a lesser extent, neutrophils. Loss of Glrx1 resulted in a trend 
towards fewer neutrophils that was not significant (Fig. 1C), whereas overexpression of 
Glrx1 did not affect neutrophils, but instead significantly decreased eosinophil 
recruitment to the lung (Fig. 3C). However assessment of the impact of Glrx1 expression 
on airway inflammation was confounded by the effects of Dox itself on HDM-induced 
inflammation, findings that are consistent with prior observations [27]. Unraveling the 
exact impact of epithelial Glrx1 on allergic airways inflammation therefore will 
necessitate additional analyses or alternative approaches to induce the Glrx1 transgene.  
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No information exists about Glrx1 and eosinophil biology, but a prior publication 
has shown that Glrx1 is important for the proper functioning of neutrophils by reducing 
dehydroascorbate to ascorbate, allowing the quenching of diffusible oxidants [28]. 
Interestingly, another study demonstrated that neutrophils isolated from Glrx1
-/-
 mice 
demonstrated impaired chemotaxis, partially due to altered actin S-glutathionylation [29]. 
This resulted in fewer total neutrophils at the site of infection and impaired neutrophil 
function, findings that may indicate the possible impact on neutrophilia in the lungs of 
Glrx1
-/-
 mice compared to WT animals, although these data did not reach significance 
(Fig. 1C). The potential ramifications of S-glutathionylation/Glrx1 for neutrophil and 
eosinophil function, and the function of other inflammatory cells in settings of allergic 
airway disease will require further investigation.  
The most striking observation from the current study was the impact of Glrx1 
manipulation on airway remodeling, particularly collagen production. HDM-exposed 
Glrx1
-/-
 mice displayed significantly elevated lung collagen compared to WT mice (Fig. 
2A, B & D), whereas HDM-exposed Epi-Glrx1 mice exhibited significantly lower 
collagen deposition compared to HDM-exposed Bitransgenic mice and rtTA mice (Fig. 
4A & C). C57/BL6 mice are known to be more prone to developing fibrosis than are 
other strains, including Balb/C [30, 31], which is a plausible explanation for the 
observations in the present study. The role of Glrx1 in airways fibrosis was not 
previously reported, and our data demonstrates a critical role for Glrx1 in controlling 
fibrotic airway remodeling in response to allergen exposure. An imbalanced redox 
environment can impact the development of experimental fibrosis [32, 33] and has also 
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been observed in patients with fibrotic lung diseases, such as idiopathic pulmonary 
fibrosis [34-37]. To our knowledge, this is the first report of Glrx1 playing a role in 
fibrotic airway remodeling in response to allergen challenge and may suggest a new 
approach for targeted therapy.  
Airway remodeling is believed to result from an imbalanced epithelial 
injury/repair response, ultimately resulting in subepithelial fibrosis. It is well-established 
that airway remodeling is a key marker of asthma severity, but recent studies also support 
a more central role for remodeling in the pathogenesis of asthma [38]. Further illustrating 
the importance of Glrx1 in allergic airways remodeling are the data showing decreased E-
cadherin and increased αSMA in stimulated lung epithelial cells lacking Glrx1 (Fig. 5) or 
in Glrx1-/-  mice (Fig. 2A and B). These phenotypic changes are consistent with those 
commonly observed in epithelial to mesenchymal transition (EMT). A role of Glrx1 in 
attenuating TGFβ-induced EMT in A549 cells has been previously demonstrated [39], 
consistent with the observations herein.  Although the existence of EMT in asthma is still 
a highly debated topic [25, 40-43], our data indicate an important role for Glrx1 in 
controlling airway remodeling and epithelial cell integrity, as Glrx1 absence results in 
loss of epithelial markers, increased expression of mesenchymal markers and enhanced 
collagen production.   
Treatments targeting established remodeling of the airways, particularly fibrosis, 
have been largely unsuccessful [44]. Early therapies for airway remodeling include 
treatment with the inhaled corticosteroid, flunisolide, which was shown to aid in 
reversing smooth muscle mass but had no efficacy in reversing established fibrosis [45]. 
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Other drugs that are used to treat idiopathic pulmonary fibrosis with some success, such 
as pirfenidone [46], could possibly be repurposed for use in asthmatics who present with 
extensive airways fibrosis. In fact, early studies indicated that pirfenidone may aid in 
reversing established fibrosis in the lungs of asthmatics, although no further studies were 
performed [47]. The increases in understanding of how redox perturbations affect disease 
pathogenesis, which encompasses increased knowledge about sources of oxidants and 
their targets, have illuminated new potential avenues for treatment. Data from the present 
study suggest that Glrx1 may be a promising target for therapeutic intervention in settings 
of airways fibrosis associated with allergic asthma, in association with improved 
















Figure 1: Analysis of HDM-induced cellular influx in the lungs of WT and Glrx1
-/-
 mice. 
(A) Scheme depicting the HDM-exposure regimen for in vivo experiments with Glrx1
-/-
 
mice. On days 0 and 7, mice were given 1ug (protein) HDM and on subsequent 
challenges beginning on day 14, mice were given 10ug (protein) HDM, indicated by 
arrows. Mice were euthanized on day 19, 24h following the last challenge. Mice (n = at 
least 8 mice/group) were exposed to PBS or HDM as indicated in (A) and BAL was 
assessed for total lung cell counts (B), macrophages, neutrophils, eosinophils and 
lymphocytes (C). (D) Western blot for Glrx1. *p≤0.05 (ANOVA) compared to respective 
PBS group. 
 
Figure 2: Assessment of HDM-induced airway remodeling in Glrx1
-/-
 mice. HDM 
protocol described in Fig. 1A was followed and periodic acid Schiff (PAS; mucus), α 
smooth muscle actin (αSMA) and Masson Trichrome (MT; collagen) stainings on lung 
sections were performed (A). Scale bar, 50 μm. (B) Quantification of mucus metaplasia 
(PAS); αSMA positivity; and MT staining.  mRNA expression of mucin gene Muc5AC 
(C). (D) Collagen content in the right superior lung lobe as measured by hydroxyproline 
assay. *p≤0.05 (ANOVA) WT HDM compared to respective PBS group; †p≤0.05 
(ANOVA) compared to WT HDM group. (E) Assessment of AHR using forced 
oscillation in response to increasing doses of methacholine (12.5, 25, 50 mg/ml). Shown 
are paramaters Rn (Newtonian resistance), G (tissue resistance) and H (Elastance). 
Statistics for (E), $p<0.05 (Least square mean) WT HDM compared to WT PBS; *p≤0.05 
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(Least squares mean) Glrx1
-/-
 HDM compared to Glrx1
-/-
 PBS; †p≤0.05 (Least squares 
mean) Glrx1
-/-
 HDM compared to WT HDM. 
 
Figure 3: Analysis of HDM-induced cellular influx in the lungs of mice expressing Glrx1 
in airway epithelial cells. (A) Scheme for Doxycycline (Dox) and HDM exposure 
regimen for experiments involving Glrx1 transgenic (Epi-Glrx1) mice. Mice were fed 
Dox- containing chow starting 7 days before the first HDM exposure and maintained on 
Dox chow for the duration of the experiment. Mice were given 1ug (protein) HDM on 
days 0 and 7, and 10ug (protein) HDM on days 14-19, and euthanized 24h after the last 
challenge. Mice (n = at least 10 mice/group) were exposed to PBS or HDM as indicated 
in (A) and BAL was collected and analyzed for total lung cell counts (B), macrophages, 
neutrophils, eosinophils and lymphocytes (C). (D) Western blot analysis of Glrx1 in 
homogenized lung tissue. *p≤0.05 (ANOVA) compared to respective PBS group; 
†p≤0.05 (ANOVA) compared to Epi-Glrx1 HDM group (grey bar).  
 
Figure 4: Assessment of HDM-induced airway remodeling in mice expressing Glrx1 in 
airway epithelial cells. Following HDM protocol in Fig. 3A, lung sections were stained 
as in Fig 1A for PAS, αSMA and MT (A). Scale bar, 50 μm. (B) RNA was isolated from 
whole lung and analyzed for Muc5AC. (C) Collagen content in the lung as measured by 
hydroxyproline assay. *p≤0.05 (ANOVA) compared to respective PBS group; †p≤0.05 
(ANOVA) compared to Bitransgenic -Dox HDM group (black bar); ‡p<0.05 (ANOVA) 
compared to Epi-Glrx1 HDM group (grey bar). (D) Assessment of AHR using forced 
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oscillation in response to increasing doses of methacholine (12.5, 25, 50 mg/ml). 
Parameters Rn, G and H are shown as in Fig 2F. Statistics for (D), $p<0.05 (Least square 
mean) Bitransgenic HDM compared to Bitransgenic PBS; *p≤0.05 (Least squares mean) 
Epi-Glrx1 HDM compared to Epi-Glrx1 PBS; †p≤0.05 (Least squares mean) Epi-Glrx1 
HDM compared to Bitransgenic HDM; #p<0.05 (Least squares mean) rtTA HDM 
compared to Epi-Glrx HDM. 
 
Figure 5: Evaluation of E-cadherin in lung tissue and epithelial cells lacking Glrx1. 
Analysis of E-cadherin mRNA expression (A) and protein content (B) from the lungs of 
WT and Glrx1
-/-
 mice following HDM protocol in Fig. 1A. WLL: whole lung lysates. (C)  
WT and Glrx1
-/-
 MTECs were stimulated with 50μg/ml HDM (protein) on days 1, 3 & 5 
and cells were harvested on day 7 for Western blot analysis for E-cadherin. Cyto, 
cytosolic lysates. (D) WT and Glrx1
-/-
 MTECs were stimulated with 5ng/ml TGFβ for 
72h and whole cell lysates (WCL) were harvested for analysis of αSMA content. (F) C10 
lung epithelial cells were transfected with scrambled (Scr) or Glrx1 siRNA and 
subsequently stimulated with TGFβ for 24h, after which WCL were harvested for 
analysis of αSMA via Western blot. *p≤0.05 (ANOVA), compared to PBS controls; ns, 
not significant. 
 
Figure S1: Schematic of the CCSP-rtTA and TetO-FLAG-Glrx1 constructs. In lung 
epithelial cells expressing Club cell secretory protein (CCSP), rtTA is constitutively 
expressed under the CCSP promoter. In the presence of Doxycycline (Dox), the rtTA 
117 
 
protein can bind to the Tet-Operon (Tet-O), driving expression of the FLAG-Glrx1 
transgene (bottom). In the absence of Dox, rtTA is unable to bind the Tet-O, thus 
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SUMMARY AND CONCLUDING REMARKS 
Summary of Intents 
 Prior work by our group has provided insight into the pathogenesis of asthma by 
investigating the role of an imbalanced redox environment in settings of allergic airway 
disease [1-4]. Through these studies, glutaredoxin-1 (Glrx1) has emerged as a crucial 
player in disease pathogenesis by regulating inflammation, airway hyperresponsiveness 
(AHR) and protein S-glutathionylation in mouse models of disease. In addition, in-depth 
studies evaluating the impact of Glrx1 in airway epithelial cells have illuminated an 
important role for Glrx1 in controlling NF-κB activation and subsequent inflammation, in 
part by controlling the S-glutathionylation of the upstream NF-κB kinase, IKKβ [5]. 
Despite these findings, little was known regarding the function of Glrx1 in cytokine-
induced NF-κB activation, downstream gene induction and S-glutathionylation of other 
NF-κB family members in airway epithelial cells. We therefore set out to examine airway 
epithelial cell responses to interleukin-17A (IL-17A), a cytokine commonly upregulated 
in the lungs of asthmatic patients, following manipulation of Glrx1 content to determine 
downstream impacts on NF-κB-dependent inflammatory cytokine production and 
glutathionylation of NF-κB family members (Chapter 2). Additionally, absence of Glrx1 
has been shown to decrease inflammation and enhance resolution of AHR in vivo [2], but 
to date minimal data exists regarding the extent of airway remodeling and fibrosis 
following chronic allergen exposure in settings of Glrx1 absence or overexpression. As a 
result, we next focused on house dust mite (HDM)-induced allergic airway disease in 
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mice globally lacking Glrx1 (Glrx1
-/-
) or in mice inducibly overexpressing Glrx1 
specifically in CCSP positive airway epithelial cells (Epi-Glrx1) in order to determine 
impacts on AHR, inflammation and markers of airway remodeling (Chapter 3). 
  
Glrx1 Control of Inflammation in Lung Epithelial Cells 
 Results presented in this thesis expand upon the role of glutaredoxin-1 (Glrx1) in 
controlling NF-κB activation and downstream pro-inflammatory gene induction in lung 
epithelial cells. We demonstrate a novel facet of IL-17A signaling associated with 
cysteine oxidation and protein S-glutathionylation (PSSG), offering new insights into the 
complex network of signaling events leading to inflammation (Ch. 4, Fig. 1 & 2). 
Previous work by our group has established that stimulation of epithelial cells with the 
oxidant, hydrogen peroxide (H2O2), results in inhibition of the canonical NF-κB pathway 
via reversible oxidation and S-glutathionylation of a critical cysteine in IKKβ (IKKβ-
SSG) [5]. Importantly, IKKβ-SSG can be reversed by Glrx1, effectively restoring IKKβ 
kinase function and downstream canonical NF-κB activation [5]. An additional study 
performed by our group showed that overexpression of Glrx1 enhances 
lipopolysaccharide (LPS)-induced NF-κB activity in lung epithelial cells in part by 
deglutathionylating IKKβ [6], consistent with previous findings. The latter study also 
demonstrated a novel feedback loop in which NF-κB positively regulates Glrx1 
expression, illustrating a redox-dependent feedback loop that enhances NF-κB signaling. 
In this thesis, a major goal was to establish a role for Glrx1 in controlling lung epithelial 
cell responses to cytokines relevant to asthma. For this reason, we utilized IL-17A, a 
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potent pro-inflammatory cytokine frequently observed in asthmatic airways that activates 
NF-κB in lung epithelial cells, resulting in heightened production of pro-inflammatory 
mediators and host defense proteins [7-12].  
The results presented in this thesis suggest that lung epithelial cell responses to 
IL-17A are governed in part by Glrx1, as absence of Glrx1 altered NF-κB nuclear content 
and downstream gene induction. Furthermore, stimulation of lung epithelial cells with IL-
17A resulted in increased oxidative stress and S-glutathionylation of NF-κB proteins, the 
latter of which was mediated by Glrx1. For the first time, we demonstrated that IL-17A 
stimulation results in increased oxidative modifications of reactive cysteines, including 
sulfenic acid (SOH) formation (Ch. 2, Fig. 2) and S-glutathionylation (Ch. 2, Fig. 3). As 
shown in previous work by our group [5, 6], these data also suggest that Glrx1 mediates 
the extent of S-glutathionylation of NF-κB proteins, namely IL-17A-induced RelA-SSG 
and IKKα-SSG (Ch. 2, Fig. 6), although IKKβ-SSG was not consistently detected in 
response to IL-17A. It should be noted that there are limitations to the detection of S-
glutathionylated proteins. Therefore, utilization of various complementary techniques in 
the future, including mass spectrometry, may help identify S-glutathionylated proteins 
that could be exploited as therapeutic targets. IL-17A can activate various downstream 
pathways, including p38 MAPK, ERK and NF-κB; to maintain focus, our studies focused 
on the impact of Glrx1 on IL-17A-induced activation of NF-κB. IL-17A-induced 
activation of NF-κB in the lung epithelium has previously been demonstrated, but until 
now, a role for Glrx1 in this process was not known (Ch. 2, Fig. 4 & 5). As described in 
the previous section, the major function of Glrx1 is deglutathionylation of target proteins, 
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a function supported by the findings of this thesis. Other functions of Glrx1 may exist, 
however, and these will be discussed later.  
IKKα is known to play a role in regulating IL-17A responses in various cell types 
[13], as well as translocating to the nucleus in T-cells and stabilizing the Th17 phenotype 
by promoting activation of the il17a gene, independent of its role in NF-κB signaling 
[14]. Our findings demonstrate a clear role for IKKα in contributing to IL-17A induced 
inflammation in lung epithelial cells, as knockdown of IKKα results in blunted 
inflammatory responses (Ch. 2, Fig. 7). Furthermore, IKKα was shown to be a target of 
Glrx1-dependent de-glutathionylation following IL-17A exposure, a process that likely 
inhibits its kinase function. This is a tentative conclusion based on existing data regarding 
its close relative IKKβ, although S-glutathionylation of IKKα may also have an impact 
on its nuclear function, independent of NF-κB. Previous work in our laboratory revealed 
that cysteine-179 of IKKβ is the target for inhibitory S-glutathionylation, as mutating this 
residue to alanine no longer resulted in IKKβ-SSG [5]. Given this knowledge, as well as 
the sequence similarity between IKKα and IKKβ, we sought to determine whether the 
homologous cysteine residue in IKKα, cysteine-178, is the target for S-glutathionylation. 
Surprisingly, mutation of this cysteine to alanine did not diminish IKKα-SSG, but instead 
resulted in increased IKKα-SSG (data not shown). Further studies are needed to 
determine the S-glutathionylated cysteine in IKKα and the precise impact of IKKα-SSG 
as this may represent a promising target in multiple cell types. Investigation of IKKα 
nuclear content in cells and lung tissues could aid in determining its subcellular 
localization following exposure to various stimuli, including IL-17A. Additionally, 
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analysis of potential interactions between IKKα and transcription factors or possible 
DNA binding analysis via ChIP or EMSA may lead to more in-depth understanding of 
the precise function of IKKα. 
 Our in vitro findings link two important features of asthma: an altered redox 
environment, with a specific role for Glrx1 and IL-17A-induced pro-inflammatory 
signaling in epithelial cells. Loss of Glrx1 in lung epithelial cells dampens 
IL-17A-induced expression of the neutrophil chemoattractant, KC. Given the strong 
evidence supporting an altered redox environment in asthma, and the specific role of 
Glrx1 in lung epithelial cells, these data represent a possible therapeutic avenue not yet 
exploited in asthma. Due to the heterogeneous effects of oxidants on proteins, targeting 
specific proteins known to contribute to disease pathogenesis may be a more appealing 
option compared to broad-spectrum approaches which alter the global redox balance of 
the lung. To further evaluate the possibility that Glrx1 may indeed be one of these 
potential targets, we performed in vivo studies to assess the effects of manipulating Glrx1 
in an allergen model of allergic airway disease.  
 
Glrx1Manipulation in HDM-Induced Allergic Airway Disease 
 Glrx1 has been shown to be increased in vivo in response to challenge with 
ovalbumin (Ova) [1] likely to counterbalance the increased oxidative stress encountered 
in allergen-induced inflammation. Furthermore, Balb/C mice lacking Glrx1 displayed 
improved respiratory mechanics compared to WT counterparts in response to Ova, while 
clinical data showed that airway function in human asthmatics negatively correlated with 
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Glrx1 content in the lung [2, 15]. These data indicate that less Glrx1 in the lung appears 
to be beneficial in settings of allergic airway diseases, including asthma. The limitations 
of studies conducted in animal models to date are multifactorial. Due in large part to the 
use of Ova as the allergen (which has limited relevance to asthma) and the atypical route 
of immunization (intraperitoneally), limited comparisons can be made to human disease. 
Alternatively, in vivo studies in this thesis utilize house dust mite (HDM), a common 
allergen to which approximately 80-85% of asthmatics are allergic [16]. The route of 
sensitization in these models is directly via the airways, simulating the events thought to 
occur in the development of asthma. The physiologically relevant initiation of allergic 
airway disease has allowed for more pertinent comparisons to human disease, although 
limitations still exist. 
Due to the lack of data regarding Glrx1 manipulation in a model of allergic 
airway disease utilizing a physiologically-relevant allergen, a major goal of this thesis 
was to investigate the impact of Glrx1 ablation or overexpression on disease pathogenesis 
in response to HDM. In contrast to previous studies, we did not observe improved airway 
function in Glrx1
-/- 
mice; in fact, we observed significant increases in Rn in Glrx1
-/-
 mice 
(Ch. 3, Fig. 2). We also observed decreased neutrophils in Glrx1
-/-
 mice (Ch. 3, Fig. 1), 
contrasting with data obtained from Glrx1
-/-
 mice on the Balb/C background exposed to 
Ova. It is important to note that all mice used in these experiments were on the C57/BL6 
background, so direct comparisons to previous experiments which utilized Balb/C mice 
are tentative at best. Strain-dependent differences in various settings, including 
inflammation, have been explored, including one such study by our group which 
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demonstrated profound differences in NF-κB activation in allergic airway inflammation 
[17]. Specifically, Balb/C mice showed elevated production of TNFα, driving NF-κB 
activation, a finding not mirrored in C57/BL6 mice [17]. This may offer a possible 
explanation for the results shown here, although further investigation is required to 
determine precise strain-specific effects of Glrx1. As a converse approach, we utilized 
mice overexpressing Glrx1 specifically in CCSP-positive lung epithelial cells when fed 
doxycycline (Dox)-containing chow. Overexpression of Glrx1 appeared to decrease 
eosinophils in response to HDM, but did not significantly affect the influx of other cell 
types to the lung (Ch. 3, Fig. 3). There was an apparent effect of Dox itself on neutrophil 
and eosinophil counts (Ch. 3, Fig. 3) and respiratory mechanics (Ch. 3, Fig. 4), which is a 
possible confounding factor in the interpretation of these data. A shorter timeframe of 
Dox administration or lower doses of Dox can be considered in future experiments in 
order to overcome these limitations. In addition, other  models of targeted overexpression 
can be considered that do not rely on the administration of Dox or other compounds with 
potential off-target effects could be utilized in future studies. 
Due to the mixed Th2/Th17 response often observed in settings of HDM-induced 
allergic airway disease, as well as our previous study evaluating epithelial cell responses 
to IL-17A, we evaluated the extent of IL-17A production in our studies. Surprisingly, we 
did not observe any increases in IL-17A gene expression or protein content in the lungs 
of HDM-exposed mice (data not shown). Furthermore, there were no differences in IL-
17A mRNA or protein that were dependent upon Glrx1 content in these mice, as absence 
or overexpression of Glrx1 had no additional effect on IL-17A production in the lungs. 
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These data may indicate that although Glrx1 status in lung epithelial cells has an apparent 
role in controlling IL-17A driven responses, the production of IL-17A following HDM 
exposure in vivo may not be dependent upon Glrx1 status. This still remains unclear, and 
further experiments are required to address this issue. It is also important to note that 
several factors, including the time course of the experiment or the dose of HDM, the 
genetic background of the mice or the lack of a mixed Th2/Th17 response in this 
particular model, could offer a possible explanation for our results. Further investigation 
of the importance of Glrx1 status in other cell types involved in HDM-driven disease, 
particularly in C57/BL6 mice, will aid in addressing these questions. 
The most striking impact in these experiments was on fibrotic airway remodeling 
following HDM exposure (Ch. 4, Fig. 3 & 4). Here, we observed a clear role for 
overexpression of Glrx1 in preventing the development of collagen deposition, 
effectively limiting subepithelial fibrosis (Ch. 3, Fig. 4), whereas a global lack of Glrx1 
resulted in enhanced fibrotic airway remodeling (Ch. 3, Fig. 2). These data provide a 
promising new therapeutic target, Glrx1, for fibrotic remodeling associated with allergic 
asthma. It is clear that Glrx1 overexpression aids in preventing collagen deposition; 
however, these studies did not address the impact of increased Glrx1 expression on 
established disease. Glrx1 is primarily a cytosolic enzyme, but findings also suggest that 
it can traffic to both the mitochondria and the nucleus [18, 19], as well as be secreted 
[20], adding another layer of complexity in trying to determine the specific function of 
Glrx1 in allergic airway disease. The function of extracellular Glrx1 still remains 
unknown, but given the extracellular function of other redox enzymes, such as QSOX 
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[21], it is possible that Glrx1 may also be involved in modifying extracellular protein 
targets.  
Future studies are necessary to determine the efficacy of Glrx1 in not only 
preventing fibrosis, but more importantly reversing established disease. Results from 
these studies may also have implications for other fibrotic lung diseases, including 
idiopathic pulmonary fibrosis, the pathogenesis of which is very poorly understood. 
Some treatments for idiopathic pulmonary fibrosis now exist (pirfenidone and 
nintedanib), but the limited efficacy of these drugs warrants the development of 
alternative strategies to halt disease progression, or even reverse existing disease [22]. If 
proven effective in reversing established fibrosis in animal models, Glrx1 may offer the 
opportunity for clinicians to use an endogenously occurring therapeutic for lung fibrosis, 
circumventing the toxic effects commonly seen with xenobiotic compounds and related 
metabolites.  
Evidence of airway remodeling following HDM exposure was observed following 
analysis of E-cadherin, an epithelial cell marker (Ch. 3, Fig. 5). Surprisingly, both E-
cadherin mRNA and protein were markedly decreased in Glrx1
-/-
 mice exposed to PBS. 
Epithelial cells from Glrx1
-/-
 mice also demonstrated baseline decreases in E-cadherin 
and enhanced responsiveness to TGFβ as evidenced by upregulation of the mesenchymal 
marker αSMA. Lung epithelial cells from Glrx1-/- mice appear to be predisposed to a 
more mesenchymal phenotype, potentially contributing to the extensive collagen 
deposition observed in the lungs of these mice (Ch. 3, Fig. 2). Because these mice 
globally lack Glrx1, it is likely that the absence of Glrx1 in other cell types, such as 
137 
 
neutrophils or macrophages, also has a substantial impact on the outcomes measured. 
Absence of Glrx1 in neutrophils impairs migration [23], a possible explanation for the 
decrease in neutrophils observed in HDM-exposed Glrx1
-/-
 mice. Our group has also 
demonstrated that Glrx1 content is increased in macrophages in response to LPS and 
macrophages from Glrx1
-/-
 mice are smaller, less abundant and display impaired NF-κB 
function [24]. Future studies assessing the importance of Glrx1 in various cell types in 
settings of HDM-induced allergic airway disease may aid in revealing cell-specific 
functions of Glrx1 in this model.  
Despite these in vivo data, very little evidence supporting a role for Glrx1 in 
human manifestations of the disease exist, likely due to the fact that its function in the 
lung is still not well understood. Our studies utilizing global Glrx1
-/-
 mice present some 
limitations and there are likely compensatory mechanisms involving other oxidoreductase 
enzymes. A more ideal system would involve mice expressing a LoxP-flanked Glrx1 
gene which could be crossed with a mouse expressing CCSP-Cre to specifically delete 
the Glrx1 gene in lung epithelial cells. Further refining of this system could also allow for 
tissue-specific, inducible deletion of the Glrx1 gene as well, similar to the tissue-specific, 
inducible overexpressing Glrx1 mouse used in this thesis (Epi-Glrx1). Despite emerging 
data supporting a role for Glrx1 in mouse models of allergic airway disease, very little 
clinical data exists regarding Glrx1. The only evidence of Glrx1 alterations in human 
asthma show that less Glrx1 in sputum, and increased S-glutathionylation correlates with 
improved airway function [15], but the underlying mechanism involved in this functional 
impact is still unknown. To date, no association between Glrx1 and airway remodeling 
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has been evaluated in human patients and more in depth studies are required to fully 
determine the clinical impact of possible mutations or absence of Glrx1. 
 
Concluding Remarks 
The role of oxidants and the subsequent impact on disease pathogenesis is a 
complex process. Cysteine oxidations, including S-glutathionylation, are emerging as 
critical mediators of protein function in a variety of diseases, including asthma. Glrx1 is a 
deglutathionylating enzyme that has been associated with asthma, but its exact role in the 
development of asthma is still not well understood. The findings presented in this thesis 
demonstrate a novel role for Glrx1 in controlling IL-17A-induced inflammation and S-
glutathionylation of NF-κB proteins, RelA and IKKα in lung epithelial cells, pointing to a 
central role for epithelial Glrx1 in controlling inflammation. In addition, a role for IKKα 
in controlling IL-17A responses was demonstrated for the first time in lung epithelial 
cells. Furthermore, in vivo data from this thesis represent a possible role for increased 
Glrx1 expression in preventing the development of HDM-induced fibrosis. These 
findings prompt future studies to determine if increased expression of Glrx1 is effective 
at not only preventing fibrosis, but more importantly, reversing established disease. 
Finally, although the exact mechanism behind these findings remains to be fully 
explained, Glrx1 may be a viable option for therapy in fibrotic lung diseases beyond 






Figure 1: IL-17A-induced inflammation and S-glutathionylation in lung epithelial cells. 
IL-17A stimulation of lung epithelial cells leads to increased activation of NF-κB and 
expression of pro-inflammatory genes. IL-17A also causes increased oxidative stress, 
resulting in elevated levels of oxidized and S-glutathionylated proteins in lung epithelial 
cells. In particular, NF-κB family members RelA and IKKα are targets for 
IL-17A-induced protein S-glutathionylation, resulting in altered NF-κB-dependent pro-
inflammatory cytokine production. RelA-SSG and IKKα-SSG can be reversed by Glrx1, 
restoring cysteines back to their native thiol state (SH) and promoting activation of NF-
κB. 
 
Figure 2: Summary of findings from IL-17A-stimulation in lung epithelial cells.  
 
Figure 3: Impact of Glrx1 status on allergic airway remodeling. In response to HDM, the 
airway epithelium produces cytokines and chemokines that recruit and activate 
inflammatory and immune cells, such as neutrophils, eosinophils, T-cells and dendritic 
cells (DC). Dendritic cells also present antigens to naïve T-cells, further enhancing the 
immune response. Production of growth factors, cytokines and other compounds, in part 
by the lung epithelium, contributes to airway remodeling as measured by increased 
smooth muscle mass, mucus metaplasia, increased collagen deposition and vascular 
remodeling. In Glrx1
-/-
 mice, allergic airway remodeling is enhanced, compared to 
Epi-Glrx1 mice which are partially protected from extensive allergic airway remodeling. 
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Figure 4: Summary of findings in Glrx1
-/-
 mice and Glrx1 transgenic mice. 
 
Figure 5: Implications and future directions. Implications of the impact of findings from 
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